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Abstract 
Deep sequencing studies of noncoding RNA in liquid biopsies are revealing a vast 
repertoire of potential biomarkers.  Ovarian cancer is a difficult-to-diagnose disease, 
urgently requiring novel and readily accessible biomarkers.   We hypothesized that urine, 
one source of liquid biopsy samples, may contain novel noncoding RNAs (ncRNAs) that 
could serve as biomarkers for ovarian cancer. We proceeded to deep sequence RNA 
extracted from urine collected from ovarian cancer patients to better understand the 
repertoire of small RNAs in this type of liquid biopsy sample.  The ncRNAs identified in 
these urine samples were predominantly microRNAs (miRNAs), ribosomal RNA (rRNA) 
fragments and tRNA fragments (tRFs).  tRFs are a group of ncRNAs, which have been 
found across the biological kingdom and are increasingly being studied for their role in 
cancer biology. Several tRFs have been studied in cancer, although not previously in 
ovarian cancer.  We have studied the expression of one specific tRF, 5’ fragment of 
tRNA-Glu-CTC (tRF5-Glu), in five different ovarian cancer cell lines.   Several variants 
of tRF5-Glu were identified and we have now confirmed the expression of tRF5-Glu in 
ovarian cancer cells by quantitative real-time PCR (qRT-PCR), Northern analysis and 
ligation PCR.  Additionally, we determined that angiogenin (ANG) plays a role in the 
biogenesis of tRF5-Glu. Furthermore, we have shown that tRF5-Glu targets the mRNA of 
the Breast Cancer Anti-estrogen Resistance 3 (BCAR3). While BCAR3 is known to 
regulate cancer cell migration and contributes to anti-estrogen resistance in breast cancer 
cells, it has not previously been studied in ovarian cancer or shown to be targeted by a 
tRF. Using synthetic mimics of tRF5-Glu and siRNAs targeting BCAR3, we were able to 
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show that tRF5-Glu expression and the knock down of BCAR3 expression inhibits 
proliferation in ovarian cancer cells. These studies demonstrate that tRF5-Glu contributes 
to the regulation of BCAR3 and provides a novel mechanism of the regulation of 
proliferation in ovarian cancer cell lines.    
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Chapter 1: Introduction 
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Etiology of ovarian cancer 
 Ovarian cancer is a highly heterogeneous disease which may arise from various cell 
types, including epithelial cells, germ cells and sex cord-stromal cells. These cells are 
present in the normal ovary (Figure 1, [1]) and some of them are even located outside the 
ovary. Despite the complex cellular origins of ovarian cancer, surface epithelial-stromal 
tumors, also named epithelial ovarian carcinomas, contribute to the majority of ovarian 
cancers and account for about 90% of all ovarian cancer cases [2, 3].  Epithelial ovarian 
carcinomas are developed from epithelial cells. Depending on the type of epithelial cell 
and location of the epithelial cells, they are then classified into five main subtypes 
including serous (fallopian tube-type), mucinous (endocervix-type), endometrioid 
(endometrium-type), clear cell (clear cell carcinoma of the endometrium-type) and 
Brenner carcinoma [4]. 
 Serous carcinomas are the most common subtype of ovarian carcinomas, and they 
are graded as either low-grade serous carcinoma (LGSC) (still looks similar to healthy 
tissue and differentiated) or high-grade serous carcinoma (HGSC) (poorly differentiated). 
The HGSC make up roughly 75% of ovarian carcinomas [5-7]. Another common subtype 
of ovarian carcinoma is mucinous carcinoma, which represents about 15% of all ovarian 
neoplasms [8, 9]. The major distinguishing feature of mucinous carcinoma is that the 
tumors are full of mucus-like fluid, while the serous tumors are filled with watery fluid. 
Other less common subtypes of epithelial ovarian carcinomas include endometrioid 
carcinoma, clear cell carcinoma and Brenner carcinoma, which may be benign or 
malignant, depending on whether the tumor cells have invaded nearby tissues. 
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Figure 1. Anatomy and biology of the ovary, fallopian tube and uterus [1]. (a) The 
fallopian tube epithelium contains two principal types of epithelial cell, secretory cells 
and ciliated cells that are responsible for fluid synthesis and egg transport. Immune cells, 
which are present in the epithelium and stroma, are thought to play a part in immune 
surveillance. (b) The ovary inset depicts the principal cells of the ovarian cortex — 
ovarian surface epithelium (OSE), ovarian stromal cells and cells of ovarian follicles at 
various stages of maturation, such as oocytes, granulosa cells and theca cells. (c) The 
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endometrium is composed of cells of the endometrial epithelium (EME) and endometrial 
stroma (EMS), which respond to systemic and paracrine signals and undergo cyclical 
changes during the menstrual cycle.  
 Although it has been highly controversial and unknown where exactly ovarian 
tumor cells originate from, the observation of different subtypes of epithelial ovarian 
carcinomas and recent molecular evidence indicate that ovarian cancer may arise from 
cells located outside of normal ovarian tissue. For example, serous carcinoma may 
originate from epithelial cells of the fallopian tube [10]; Both endometrioid carcinoma 
and clear cell carcinoma are associated with endometriosis (abnormal growth of 
endometrial tissue), which is the most plausible source of ovarian carcinogenesis [11-13]. 
The exact derivation of mucinous carcinoma and Brenner carcinoma remains unclear, but 
recent data suggest that certain subsets of mucinous carcinoma and Brenner carcinoma 
exhibit a shared clonal relationship and may have similar oncogenesis from the 
transitional-type epithelium located at the tubal-mesothelial junction [10, 14, 15]. In 
summary, the evidence provides insight into the development of epithelial ovarian 
carcinomas, but more effort is need to further characterize the exact origins of each type 
of ovarian tumors.  New understanding of ovarian cancer etiology may help develop 
more rational approaches of detection, treatment and prevention of ovarian cancer. 
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Pathogenesis of ovarian cancer 
 Cancer is a disease characterized by the build-up of mutations and epigenetic 
changes. Many genetic alterations and other molecular defects have been recorded in 
various subtypes of ovarian cancer. The majority of the genetic abnormalities include 
mutations that either activate or inactivate genes controlling the growth and division of 
ovarian cancer cells.  Such genes are known as oncogenes (those that are activated) or 
tumor suppressors (those that are inactivated), corresponding to their role in cancer 
biology. The well characterized genetic abnormalities including activation of oncogenes 
and inactivation of tumor suppressor are summarized for the major subtypes of epithelial 
ovarian carcinoma (Table 1, [1, 3, 10, 16, 17]). 
Carcinoma subtype Possible cellular origin Molecular features 
HGSC 
Ovarian surface epithelium; 
fallopian tube epithelium 
Mutations in BRCA1, BRCA2 
and TP53 
LGSC 
Ovarian surface epithelium; 
fallopian tube epithelium 
Mutations in BRAF and KRAS 
Mucinous 
carcinoma 
Unknown; Transitional-type 
epithelium found at the 
tubal-peritoneal junction 
Mutations in BRAF, ERBB2, 
KRAS and TP53 
Endometrioid 
carcinoma 
Endometrial epithelial cell 
Mutations in CTNNB1, PTEN, 
PIK3CA and BRCA1 
Clear cell 
carcinoma 
Endometrial epithelial cell 
Mutations in KRAS, PIK3CA, 
PTEN and TP53 
Brenner carcinoma 
Unknown; Transitional 
metaplasia and Walthard 
cell nests 
Mutations in CDKN2A, KRAS 
and PI3KCA 
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Table1. Cellular origin and molecular pathogenesis of major ovarian epithelial 
carcinoma [1, 3, 10, 16, 17]. Although these mutations are associated with the type of 
ovarian cancer listed, there is great variability between samples and it remains difficult to 
confirm those tumors that share features of both types, such as low-grade versus high-
grade serous carcinoma. 
 
 The primary genetic changes leading to ovarian cancer still remain unclear. 
Families with germline mutations, such as in the tumor suppressor genes BRCA1 and 
BRCA2, are found to be at higher risk for ovarian cancer. BRCA1 and BRCA2 encode 
tumor suppressor proteins involved in DNA repair pathways. Impairment of DNA repair 
pathways allows the accumulation of genetic mutations and eventually leads to genomic 
instability that expedites tumor formation. Together, the germline mutations of BRCA1 
and BRCA2 account for approximately 10 to 15% of all ovarian cancer cases [18]. In 
addition, a rare hereditary genetic syndrome named Lynch Syndrome, which is often 
associated with mutations in DNA mismatch repair genes including MLH1, MSH2, 
MSH6 and PMS2, is consider to increase the risk of developing ovarian cancer [19, 20]. 
Mutations of those genes lead to uncontrolled growth and unchecked division of cells and 
accounts for about 10 to 15% of hereditary ovarian cancer.  Additional germline 
mutations and the relationship between other rare genetic syndromes and increased risk 
of ovarian cancer still remains unclear and the identification would provide meaningful 
clinical implications. 
  Unlike germline mutations, somatic mutations in ovarian cancer are not inherited 
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from a parent and are acquired over the lifetime. The mutations are only present in certain 
cell types and representative mutations of oncogenes and tumor suppressors are listed in 
Table 1.  During the oncogenesis of ovarian cancer, the loss and mutations of TP53 is one 
of the most frequent genetic alterations that has been observed in both sporadic and 
familial cases [21, 22].  
 Despite the specific DNA mutations of oncogenes and tumor suppressor identified, 
the comparison of RNA sequencing data from normal and ovarian cancer patient samples 
also brought about the discovery of tumor-specific RNAs, especially miRNAs [23, 24]. 
miRNA is known to regulate gene expression and control function of encoded proteins 
through mRNA turnover and the translation regulation [25]. The altered expression 
patterns and functions of miRNAs associated with oncogenesis of ovarian cancer may 
also be categorized into oncogenes or tumor suppressors [26]. Many miRNAs have been 
revealed to play carcinogenic roles in ovarian cancer development and indicate the 
prognosis of ovarian cancer [23, 24, 27]. Further study of the roles and basis of miRNA 
function in ovarian cancer may provide new strategies for tumor detection and treatment.    
 The risk factors causing the somatic mutations of ovarian cancer are highly diverse. 
Although chemical carcinogens with mutagenic ability have been recorded to contribute 
to the development of multiple cancers including ovarian cancer [28, 29], continuous 
ovulation and disrupted hormone conditions remain to be another important risk factor 
for ovarian cancer. Following the release of oocytes, quiescent epithelial cells on the 
surface of the ovary need to proliferate to repair the damage to the ovarian surface, which 
increases the risk of gaining spontaneous mutations during proliferation.  Thus a long 
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period of ovulation and infertility is thought be one of the fundamental causes of 
epithelial ovarian carcinoma [30, 31].  Steroid hormones including estrogen and androgen 
are important for the growth of ovarian epithelial cells. Previous studies suggest that 
estrogen therapy and hormone therapy for menopausal women increase the risk of 
developing ovarian cancer due to longer exposure to these hormones [32-35]. Other risk 
factors including environmental risk factors with psychosocial and psychological stress, 
aging, obesity and smoking have also been investigated and found to contribute to 
increased ovarian cancer risks, but more details and the molecular basis for the risk 
factors need to be studied in depth to confirm their connections to the carcinogenesis of 
ovarian cancer [36-40].   
 
 
 
 
 
 
 
 
 
  
  
 
  9 
 
Early detection and diagnosis of ovarian cancer 
 Ovarian cancer is a leading cause of cancer mortality among women worldwide, 
with an expected five year survival of less than 30% [17]. Unfortunately, ovarian cancer 
is frequently diagnosed at an advanced stage (Stage III & Stage IV), while the five-year 
survival rate of women that are diagnosed at an early stage can reach up to more than 
90% [41, 42]. Although early detection of ovarian cancer is one of the most significant 
factors that ensure effective treatment of the patients, the difficulties of early detection 
are attributed to several obstacles including the inaccessible nature of the ovary on 
physical exam and the absence of specific symptoms until metastasis [43, 44]. Thus, there 
is a critical need and these would be a significant benefit if effective and reliable early 
detection strategies for ovarian cancer were to be developed. 
 Imaging technologies are often used to measure the size and spread of tumors in 
clinical examination, and they are also being applied in the detection of ovarian cancer. 
The most widely and commonly used technique is the Transvaginal Ultrasound (TVU) to 
examine pelvic organs [45]. Even though TVU has been shown to be effective to assess 
the pain and pressure in the pelvic region, most adnexal masses as well as other 
gynecologic symptoms such as abnormal bleeding and fibroids, TVU is not a primary 
early-detection method as it is not able to differentiate malignant and benign tumors 
efficiently. Other imaging technologies including Magnetic Resonance Imaging (MRI) 
and Computed Tomography (CT) are also used to evaluate and stage adnexal masses, 
while they are both limited in the early diagnosis of ovarian cancer due to the inability to 
  10 
distinguish benign and malignant neoplasms [45, 46].  
 New advances in genomic and proteomic techniques have led to the discovery of 
many potential biomarkers. Accessible patient samples including blood and urine are 
being studied for identification of biomarkers and these samples are now often called 
liquid biopsies [47, 48]. Candidate biomarkers are not only limited to proteins encoded 
by susceptible genes, but also include cell-free DNA, various types of RNA, lipids, 
chromatin alterations and even circulating tumor cells [49-56]. 
 The most comprehensively studied and widely used circulating biomarkers for 
ovarian cancer are two proteins: cancer-antigen 125 (CA-125) and human epididymis 
protein 4 (HE-4). CA-125 is a transmembrane protein encoded by the mucin 16 (MUC16) 
gene and elevated serum level of CA-125 has been found in more than 80% of patients 
with advanced ovarian cancer [57]. In addition, the serum level of CA-125 is also 
regarded as a standard to determine patient’s response to treatment as well as predict the 
prognosis after treatment. High levels of CA-125 are often associated with poor survival 
and recurrence of ovarian cancer [58-60]. The detailed biological functions of CA-125 
still remains to be defined, but CA-125 is an effective and useful biomarker for ovarian 
cancer detection following initial treatment. However, the use of CA-125 for early 
detection of ovarian cancer is restricted due to the lack of sensitivity and specificity. For 
specificity, although used as a biomarker for ovarian cancer, elevated levels of CA-125 
have also been observed in other cancer sites including breast cancer, lung cancer and 
endometrial cancer as well as other diseases of the ovary and even pregnancy, which 
often produces false positive early detection for ovarian cancer [58, 61, 62]; For 
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sensitivity, even though highly expressed in most ovarian cancer patients with high grade 
disease, more than half of patients at early stages of ovarian cancer fail to exhibit elevated 
levels of CA-125 in blood. Thus, CA-125 may lead to false negative results for early 
stage ovarian cancer before the onset of symptoms [62-64]. Another potential proteomic 
biomarker used for ovarian cancer detection is the HE-4 protein, which is encoded by the 
WAP four-disulfide core (WFDC) gene [50, 65]. With similar sensitivity to detect 
ovarian cancer patients at advanced stages like CA-125, HE-4 does give a better 
distinction between benign and malignant ovarian tumors [66]. However, there remains a 
lack of specificity for the measurements of HE-4 to detect ovarian cancer at early stage 
and even differentiate ovarian tumors and tumors with similar non-ovary origins [65, 67, 
68]. 
 As described earlier, RNAs, especially miRNAs have been revealed to be expressed 
at different levels in ovarian tumors compared to normal tissues, and different subtypes of 
ovarian cancer exhibit diverse profiling of miRNA expression 
[23, 24, 51, 52, 69]. In addition, recent evidence has shown that several cell-free miRNAs 
can circulate in body fluids such as urine and blood in normal and ovarian cancer patients 
[70, 71].  Expression profiles of circulating miRNAs are strongly related to clinical 
signatures in ovarian cancer patients [52, 72]. Due to their representation of the 
physiological state and potential function in ovarian cancer, these ncRNA molecules may 
serve as novel diagnostic biomarkers for ovarian cancer detection, especially early 
detection. 
 Various studies have identified many ovarian cancer-associated circulating 
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miRNAs as possible diagnostic biomarkers of ovarian cancer [73]. The advances in 
nucleic acid analysis technologies, such as high-throughput small RNA deep sequencing, 
make it feasible for us to seek novel miRNA as well as other ncRNA biomarkers from the 
tissue samples or the liquid biopsies of ovarian cancer patients. A recent report 
characterized a tRF originating from 3’end of Lys tRNA, originally called miR-1274a, as 
a potential prognostic biomarker in patients with high-grade serous ovarian cancer [74, 
75]. It raises the possibility that, besides circulating miRNA, other ncRNA molecules 
including tRFs could also serve as potential diagnostic and prognostic biomarker for 
ovarian cancer detection. Toward this effort, we have identified extracellular RNAs 
(exRNAs) in urine from ovarian cancer patients. Surprisingly, we found some of the most 
highly expressed ncRNAs in these samples are tRFs.   
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The introduction of tRFs is adapted from published work:  
Diebel et al. Beyond the Ribosome: Extra-translational Functions of tRNA Fragments 
Biomarker Insights, Jan 28th 2011. doi: 10.4137/BMI.S35904. 
 
What are tRFs? 
High throughput sequencing studies continue to identify an expanding array of 
small ncRNAs [76].  These newly identified small ncRNAs are derived from many types 
of primary RNA transcripts that ultimately give rise to the small, biologically functional 
molecules of miRNAs, rRNA fragments, small nucleolar RNA (snoRNA) fragments, 
tRFs, and others [77].  Early high throughput sequencing studies of small ncRNAs 
generally regarded rRNA and tRFs as nothing more than contaminating degradation 
products and sequences of little interest for biological study [76].  It was assumed that 
these fragments were naturally produced, inert RNAs derived from the functional 
parental rRNA and tRNA molecules.  However, with improving bioinformatic 
methodologies these once dismissed RNA fragments are now being recognized for their 
importance in many biological pathways including the regulation of translation, stress 
responses, proliferation and other aspects influencing human disease [76-80]. tRFs are 
now known to be purposefully processed from both mature and pre-tRNAs.  tRFs 
represent one group of small ncRNAs currently undergoing a new wave of investigation 
centered primarily on the control mechanisms resulting in their biogenesis and 
determining their biological function within various cell types and cell growth conditions 
[76-90].  
  14 
 
Biogenesis of tRNAs and tRFs   
tRNAs are among the most abundant RNA molecules in a given cell, constituting 
as much as 4-10% of total cellular RNA [78].  The fundamental role of tRNAs, where a 
charged tRNA delivers an amino acid to a growing peptide chain within the ribosome, is 
well studied [91].  The biogenesis of tRNAs begins with their transcription by RNA 
polymerase III (pol III) from a type 2 RNA pol III promoter.  After transcription, several 
modifications are made to the tRNA transcript in the form of endonucleolytic cleavages, 
exonucleolytic trimming, non-templated nucleotide additions, and multiple single base 
modification events.  These events occur prior to the addition of a single amino acid to 
the 3’ end of the mature tRNA (Figure 2).   The highly modified and aminoacylated 
tRNA may then be used within translation.   
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Figure 2. An overview of the process leading to tRNA and tRF biogenesis.  tRNAs 
are initially processed from pre-tRNAs into mature tRNA by removing nucleotides that 
constitute a 5’ leader by ribonuclease P (RNase P) cleavage and then the  3’ tail is 
removed through cleavage of the tRNA primary transcript by RNase Z.  A select group of 
tRNAs harbor introns and must be further processed by a complex known as the tRNA 
splicing endonuclease, a complex including CLP1 and other proteins (not included in this 
figure) [90].  In the figure representative enzymes are listed as tRNA modifying or 
cleaving enzymes and are not meant to be inclusive of all such enzymes. It is highly 
likely that additional modifying and cleaving enzymes for tRNAs will be identified in the 
future.  
 
The biogenesis process used by cells to make mature aminoacylated tRNAs 
consists of many well-regulated steps that result in the interaction of tRNA molecules 
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with several tRNA modification enzymes [80].  Paramount to understanding tRF 
biological function is the need to understand tRF biogenesis.  Recent research has 
centered on deducing how a tRF is generated from a molecule essential for protein 
translation, and which pathways are used to generate mature tRNAs versus those used to 
generate various tRFs. 
 
Nomenclature of tRFs  
Highlighting the emergence of a new field of scientific study, the nomenclature of 
tRFs has had a varied beginning [92]. In earlier studies of tRFs, the fragments were 
simply called tRNA halves and included 5’-half-tRNAs as well as 3’-half-tRNAs [83, 88, 
92].  In another related study the tRFs were referred to as tRNA-derived small RNAs 
(tsRNA) [84].  Additional labels have been used for tRFs based on their size, expression 
or function.  In one such study, tRFs expressed in response to stress were called stress 
induced tRNAs (tiRNA) [88].    In another study, tRFs were named for the location of the 
cleavage site, thus, those cleaved from the 3’ end of the tRNA were called tRF-3 [85].   
Meanwhile, tRFs expressed in response to hormone stimulation have been referred to as 
Sex HOrmone-dependent tRNA derived RNAs (SHOT-RNAs) [89].  Figure 3 describes 
frequently identified tRFs and the pathways leading to their biogenesis.  As more 
information becomes available about the function of this group of ncRNAs, a more clear 
method of naming them will also evolve.   
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Figure 3. Nomenclature of tRFs.  The nomenclature for tRFs is inconsistent due to their 
recent identification most often as part of deep sequencing data sets.  Early terminology 
included tRF-1 or 3’U tRF for the trailing sequence cleaved by RNase Z during 
maturation [85, 93]. The tRFs generated following CCA addition and cleaved in the T 
loop were designated tRF3 or 3’CCA tRF, while the 5’ tRFs generated after cleavage by 
RNase P were designated tRF-5, 5’tRFs or 5’leader-exon tRFs [85, 87, 93]. These 
fragments are smaller than halve tRNAs and range in size from 13 to 20 base pairs [93].   
The tRNA halves are larger and the expected size is 30-40 nucleotides, however, this 
appears to be quite variable [92-94]. Megel, et al. propose a universal naming where the 
letter corresponds to the extremity of the tRNA and the number (5 or 3) to the cleavage 
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site such as tRF3T  for a 3’ tRF generated by cleavage in the T loop [92]. Utilizing the 
proposed general naming scheme the newly identified intermediate tRFs would be 
tRF53DT. Multiple arrow heads are used to designate regions cleaved by ANG that are 
often variable and may occur at any point in the anti-codon loop [94]. While a single 
arrow head is used to designate potential Dicer, RNaseP sites or possibly novel RNase 
cleavage [93].   
 
The biogenesis of tRFs is highly conserved 
Initially regarded as degradation products, tRFs were often excluded from 
published studies and as such were not considered as potential biomarkers in earlier 
studies [76]. However, the expression of tRFs in response to stress is evolutionarily 
conserved and includes both prokaryotes and eukaryotes, suggesting a functional role of 
biological importance [78, 79, 95, 96]. Furthermore, the processing of tRFs from mature 
tRNAs has been shown to occur by an evolutionarily conserved group of proteins, the 
RNases.  RNases that have been shown to generate specific types of tRFs include PrrC, 
RNase T2 (Rny1), Dicer, RNase Z, RNase P and ANG, and it is also expected that this 
list may grow as more fragments are studied [79, 81, 85, 87, 95]. While these studies 
have provided the groundwork for understanding that the biogenesis of tRFs is a 
conserved and regulated process, further investigation is needed to determine the ultimate 
molecular function of specific tRFs.  Additionally, improved detection strategies are 
needed for the identification of tRFs within biological samples.   Once characterized, 
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these tRFs may prove to be robust biomarkers that reveal critical information about a 
patient’s current state or future risk of disease [97, 98].  
Interestingly, tRFs observed in many high throughput studies were assumed to be 
derived from mature tRNAs because the expected cleavage, non-templated nucleotide 
additions, and base modifications required to generate a mature tRNA had taken place 
prior to generation of the tRF [76, 80]. tRNAs are initially processed into a mature tRNA 
by removing nucleotides that constitute a 5’ leader or 3’ tail through cleavage of the 
tRNA primary transcript by RNase P and RNase Z respectively. It has recently been 
shown that the 3’ trailer sequence may form a subset of the functional tRFs and this 
subset has been designated as tRF-1 indicating their biogenesis is neither 3’ nor 5’ from 
the mature tRNA [85]. The series of tRF-1 include tRF-1001 which was shown to impair 
cellular proliferation, when knocked down with siRNA. Thus, biogenesis of pre-tRNAs 
does result in the formation of a functional class of tRFs [85].  
Other subsets of tRFs are generated from the splicing of intron sequences and the 
cleaving of mature tRNAs [90, 92]. After these cleavage events, the tRNAs gain three 
additional nucleotides (CCA) at their 3’ ends which are required for their subsequent 
aminoacylation [99]. Mature tRNAs are also modified at as many as 8 or more base pairs 
during maturation into a biologically functional molecule [80, 99, 100]. These 
modifications of tRNAs may include but are not limited to methylation events such as 
m1A, m1G, N2, N2-dimethylguanosine [80]. Interestingly, some nucleotide modifications 
by methyltransferases have been reported to block cleavage into tRFs, while other 
modifications of tRNA, specifically a 2’-O-methylation event in the anticodon loop, have 
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been shown to enhance cleavage into tRFs in yeast [80, 101-103]. However, many of the 
known mechanisms of processing tRNAs into tRFs have been defined in organisms other 
than mammals and these mechanisms will need to be further confirmed for their 
conservation in higher eukaryotes as the field of tRF biogenesis advances.    
 
RNases involved in the cleavage of tRNAs into functional tRFs 
The RNases including Dicer, RNase Z, and ANG have all been studied for their 
role in cancer cells and as potential biomarkers for predicting cancer risk [104-107]. All 
three enzymes have also been studied using siRNA knockdowns to confirm that they 
have a role in the generation of tRFs in cancer cells [81-89]. In contrast to tRF 
biogenesis, miRNA biogenesis is a well-characterized process and frequently requires 
initial processing by Drosha and Dicer to produce mature miRNAs.  However, the 
generation of tRFs is thought to be independent of Drosha cleavage, while a subset of 
tRFs are thought to be generated in a Dicer dependent manner [81, 104, 108].    
 One example of a tRF generated by Dicer cleavage is the primer-binding small 
noncoding RNA (PBSncRNA), which was determined to be a tRF derived from tRNA-
Lys3 [109]. Knockdown of PBSncRNA allows replication of HIV and PBSncRNA has 
been identified in argonaute 2 (AGO2) complexes suggesting that the expression of this 
tRF may target HIV replication. It has been proposed that tRFs may be part of a host 
response to defend against viral infection, thus, it is hopeful that the function of 
PBSncRNA will be confirmed to block HIV replication in future studies. 
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RNase Z also known as ELAC2 has been well studied for its role in the 
production of mature tRNAs by trimming off excess nucleotides at the 3’ end of tRNA 
primary transcripts. RNase Z has recently been shown to be important in generating a 
subset of tRFs, particularly tRFs generated from the cleavage of long 3’ end tails from 
primary tRNAs [82, 85]. In addition, to its role in generating tRFs, the nuclease activity 
of RNase Z can also be guided by tRF to other target RNA molecules inside cells in trans 
to regulate expression [83]. Thus, RNase Z is currently being used to develop a targeted 
therapeutic approach for cancer treatment based on its ability to recognize and cleave any 
pre-tRNA-like complex, a method known as TRUE Gene Silencing [110].   
The discovery that RNase Z could be engineered to target RNA molecules led 
Elbarbary et al., to question if RNase Z bound to endogenous tRFs [82].  
Immunoprecipitation of RNase Z and isolation of bound RNA showed that a number of 
ncRNAs were bound to RNase Z.  One of the ncRNAs identified in this study was 5’-
half-tRNAGlu.  The authors went on to show that 5’-half-tRNAGlu was acting as a small 
guide RNA (sgRNA) and directly regulated the expression of the PPM1F mRNA a 
protein that has been shown to induce apoptosis in HeLa cells when over expressed [82]. 
Of the numerous RNases identified in the human genome, one of the best 
characterized nucleases shown to be used in the processing of tRNAs to tRFs, is ANG.  
ANG is a member of the RNase A superfamily and is also known as RNase 5.  ANG is 
well studied for its activity in cleaving mature tRNAs [79]. Several studies have shown 
that ANG activity increases its cleavage of tRNAs in response to specific stimuli such as 
nutritional deficiency, hypoxia, heat shock and oxidative stress [79, 111-113]. In 
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addition, human respiratory syncytial virus (RSV) infection has been shown to stimulate 
tRF formation through ANG cleavage using lung cancer cells as host for the RSV 
infection [114]. Within this study the infection of lung cancer cells with RSV was shown 
to specifically increase the formation of tRF-Glu, tRF-Gly and tRF-Lys.  Interestingly 
infection with a virus from the same family, human metapneumovirus, did not increase 
the expression of these tRFs showing that there are both substrate specificity in the 
generation of tRFs and a complex regulatory mechanism governing the activation of 
ANG to act on tRNAs in order to generate tRFs [114]. The specificity of ANG in 
producing tRFs in response to RSV infection was determined by knocking down the 
expression of the RNA cleaving enzymes ANG, Dicer, Drosha, RNase Z, and RNase L.  
Only the knock down of ANG significantly reduced tRF formation in response to RSV 
[114].  
Mounting evidence from high throughput sequencing studies suggests that many 
additional cleavage sites in tRNAs may exist and that one part of the molecule is 
generally found at higher levels suggesting that these ncRNAs are functionally active 
[94]. Interestingly the total RNA cleavage of a given tRNA is only about a tenth of the 
total available tRNA suggesting that tRFs are generated from a subpopulation of the total 
mature tRNA for a given tRNA transcript [113, 115]. Further confirmation that 
angiogenin and tRNA availability are important in the generation of tRFs came from a 
comprehensive study by Saikia et al [113]. In this study several conditions including 
oxidative stress, hypertonic stress and increased angiogenin expression were tested and a 
micro array based assay was used to detect tRFs [113]. One of the central findings in this 
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study is that different types and lengths of stress result in differing patterns of tRF 
generation.  As this new area of research moves forward, it will be important to validate 
each testing condition in various cell types rather than to assume that what was found in 
one set of conditions will be the same in all other cell types and cell growth conditions.  
In a study of the protozoan, Tetrahymena thermophila, half tRNAs were 
generated during early amino acid starvation [116]. In this study starvation for all amino 
acids or for any one of the essential amino acids resulted in tRF formation. Tetrahymena 
thermophila is an excellent model for studies of amino acid starvation induced tRNA 
fragmentation due to the need of this organism to rapidly respond to changing 
environmental cues.  In contrast, studies of tRNA fragmentation in response to starvation 
in HeLA cells, was not corrected by the addition of essential amino acids as it was in 
Tetrahymena [86, 116]. However, tRNA fragmentation was blocked by siRNA shutdown 
of ANG [86].  
The known role of ANG in the generation of tRFs may collide with the role of 
this same protein in tumor immunology.  ANG was known to be elevated in the process 
of angiogenesis as early as 1987 and continues to be a potential biomarker for tumors in 
numerous tissue sites and a potential target for therapeutic intervention [117-120]. 
Furthermore, circulating antibodies against ANG have been found to be a sensitive 
biomarker for osteosarcoma and are thought to play an important role in tumor 
immunology for this cancer type [121].   
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Function of tRFs 
Although tRFs have been linked to immune function by their location in 
exosomes, the specific role of individual tRFs is currently not well characterized [122-
124]. Early studies examined the collective extracellular tRF function with one study 
finding that tRFs in the conditioned media from bladder carcinoma inhibited the growth 
of endothelial cells [125]. However, at that time it was not possible to characterize the 
exact tRF responsible for the inhibitory action because methods did not exist to sequence 
the tRFs in media.  Studies confirming the cellular function of tRFs have been 
summarized in Table 2.   
Table 2. Representative studies of tRF function. 
 
  tRF  Function  Cell type         Study 
 Alteration of cell phenotype in response to tRF expression 
 5’tRFs  Isolated from the 
media of a urinary 
bladder carcinoma 
cell line and used 
to inhibit 
endothelial cell 
growth.   
 Bovine 
endothelial 
cells 
 [125] 
 3’tRFSer  Regulates cell 
proliferation 
 HCT116, 
DU145, 
LNCaP 
 [85] 
 5’tRFVal  Cleavage of tRNAs 
during stress 
 HepG2  [87] 
 5’tRF and 
3’tRFHis 
 Ribosomal bound 
tRFs change with 
differing growth 
conditions 
 Yeast 
ribosomes 
 [126] 
 5’tRFGlu, Gly, 
Lys 
 Increased tRF 
expression in 
 A549 
primary small 
 [114] 
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response to 
infection by RSV. 
alveolar 
epithelial 
cells 
 5’ leader  Neurodegeneration 
motor neuron loss, 
over expression of 
5’ leader tRFs. 
 kinase dead 
CLP1 mice 
 [127] 
 5’tRFAsp, His, 
Lys  
 siRNA to Estrogen 
and Androgen 
Receptor reduce 
expression of 5’ 
fragments.    
Androgen receptor 
dependent 
cleavage, increases 
proliferative 
response. 
 MCF7, BT-
474, LNCap 
  
 LNCap-FGC 
 [89] 
 tRFs from 
all 20 
amino acids 
 Predicted in 
drosophila to bind 
conserved Seed 
sequences. Showed 
significant gene 
ontology 
enrichment brain 
activity and aging. 
 Bioinformatic 
approach not 
confirmed in 
cell lines. 
 [128] 
 5’tRFGlu,Asp, 
Gly,Tyr 
 Displaces YBX1 
an RNA binding 
protein allowing 
stabilization of 3’ 
UTRs of oncogenic 
transcripts. 
 MDA-LM2, 
four tRFs 
transfected in 
mice.  
 [94] 
 Targeting a specific mRNA through Seed binding in the 3’ UTR  
 3’tRFLys3  Loaded into AGO2 
complexes and 
targets HIV primer 
binding site. 
 HeLa cells  [109] 
 3’tRFGly  A DICER 
substrate, represses 
RPA1. 
 HEK293, 
normal B 
cells, lost in 
 [129] 
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subset of 
lymphomas 
 Targeting a specific mRNA by acting as a small guide RNA 
 5’tRFGlu  Down regulates 
PPM1F transcript 
 HEK293  [82] 
 tRFs Regulating Translation 
 5’-tiRNAs  5’-tiRNAs but not 
3’-tiRNAs have a 
distinct inhibitory 
effect on 
translation 
 U2OS  [88] 
 5’tRFAla  Induces stress 
granule formation. 
 U2OS  [130] 
 5’-
tiRNAAla,Cys 
 YB1 is the only 
tiRNA binding 
protein needed for 
tiRNA induced 
stress granule 
formation 
 U2OS  [131] 
 5’tRFVal  Binds small 
ribosomal subunit 
and blocks 
translation 
 Haloferax 
volcanii 
 [96] 
 5’tRFGln  Inhibits protein 
translation. 
 HeLa  [132] 
 
 
A general function of tRFs was shown to be the inhibition of translation by 
disrupting the cap-binding complex eIF4F [131]. More recently, the function of a subset 
of tRFs generated by RNase cleavage has been shown to block YB-1 binding of target 
transcripts [94]. The YB-1 protein (YBX1 gene) is an RNA binding protein that is 
frequently over expressed in cancer cells and plays a significant role in RNA translation 
and stability [94, 133]. YB-1 binds to tRF-Ala and specifically inhibits translation [94]. 
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Interestingly, tRF-Ala is one of the tRFs capable of forming a G-quadruplex structure due 
to the oligo-G nucleotides it contains and this structure is required for translational 
repression [134]. Earlier studies of G-quadruplex structures showed they cause resistance 
to nuclease cleavage and have anti-proliferative activity in cancer cells [135].  
Recent studies have shown that cells treated with mimics of 5’-tRFs form stress 
granules.  The synthetic mimics of 5’tRFs tRF-Ala, Gly and Val were all tested on U2OS 
cells and stress granules were visualized [130]. Stress granules are formed in response to 
cellular stress and they play a role in reprogramming the cell to stop transcription and 
translation in response to cellular stressors [131]. The specific set of 5’tRFs have been 
called tiRNAs for stress induced tRFs. Translational inhibition has been linked to 5’tRFs 
(5’tiRNAs) by a mechanism, which is independent of phospho-eIF2alpha translational 
repression [136]. Synthetic mimics of 3’tRFs (3’tiRNAs) did not cause stress granule 
formation.  Taken together these studies confirm that one role of a subset of 5’-tRFs is a 
rapid response to down regulate RNA translation during stress [136]. 
Modifications of tRNAs are ubiquitous, with as many as 100 or more different 
modifications and 8 or more modifications per tRNA [100, 137]. Therefore, it has been 
hypothesized that modifications may alter the cleavage into tRFs. This is an area that will 
require a great deal of study in the future and will be enhanced by new techniques such as 
AlkB-facilitated RNA methylation sequencing (ARM-seq) described by Cozen et al. 
2015 [80].  ARM-seq allows the removal of modifications so that high throughput 
sequencing is not blocked by hard stop RNA modifications.  
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The loss of one such modifying enzyme, NSUN2, resulted in widespread 
neurological abnormalities in mice and specifically altered the expression of 5’tRFs 
[102]. NSUN2 is a tRNA methyltransferase known to be mutated in neurological 
disorders as well as cancer.  This is one of the first confirmations of an enzyme 
functioning in the regulation of tRNA fragmentation resulting in human disease.  With 
over 100 potential modifications, it is expected that tRF expression and function will be 
altered in many ways as yet undefined.  This is an area of research awaiting much study 
in tumor biology and elsewhere.   
 
tRFs as potential biomarkers 
The variable expression and function of tRFs are just now being elucidated.  It 
will take some time to identify clinical applicability and to determine if these small RNAs 
have potential as biomarkers of disease.  Bioinformatic methods to identify tRFs in deep 
sequencing studies are rapidly evolving and in some cases will allow the mining of 
historic data sets, where tRFs were initially discarded from analysis [76, 126, 138]. 
Revisiting data sets where expression of tRFs may be correlated with clinical 
characteristics will allow the identification of potential tRF biomarkers in well 
characterized samples.  Retrospective studies must be conducted with care and 
understanding of the complication of tRNA and tRNA-like abundance in the human 
genome [138]. Telonis et al., outline difficulties in interpreting tRF data in high 
throughput sequencing studies [138]. Such difficulties include but are not limited to the 
repetitive nature of tRNA sequences in genomes, the complexity of multiple isoacceptors 
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for each amino acid, and the existence of base changes thought to be a result of 
modifications.  Bioinformatic analysis must be accompanied by a clear description of the 
criteria used for data set analysis and then be followed by experimental confirmation.  
tRFs have been well documented to exist in patient serum and other convenient 
biological samples at levels similar to miRNAs [123, 125, 139, 140]. In prospective 
studies, consistent methods for patient sample collection and analysis of exRNAs will be 
critical as biomarker studies of tRFs move forward [141].  The methods utilized in each 
study must be carefully controlled and reported if data is to be comparable across samples 
and between studies [142]. For example the sample preparation, sample storage and RNA 
collection methods must be fully described and consistent for all patients.  The method of 
RNA isolation and amplification if different between studies may impact the resulting 
repertoire of fragments obtained and characterized.  The development of biomarkers is a 
complicated process and as tRFs make their way into the biomarker pipeline, it will be 
necessary to apply past experience to develop robust biomarkers with clinical value [143, 
144]. 
tRF expression has been detected in cancer patient samples from multiple tissue 
sites and accessible samples [123, 125, 129]. A study of B cell lymphoma found that tRFs 
were down-regulated in lymphoma cell lines and primary biopsies as compared to control 
B cells [129]. While a study of tRF expression in prostate cancer patients, found that tRFs 
were increased in metastatic samples [140]. Studies of tRF expression in cancer cell lines 
have revealed a diverse array of tRF expression and have been useful as model systems to 
study the function of tRFs.  Mechanistic studies of tRF expression in the response to 
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hormones in prostate and breast cancer cells suggest that tRFs enhance cell proliferation 
and that their expression is tissue dependent [85, 89, 123, 145]. 
tRFs may act like miRNAs and if confirmed this could mean that one tRF may 
regulate multiple mRNA targets [109, 129]. Defining the biological expression and 
function of tRFs is reminiscent of the early studies of miRNAs, where much controversy 
occurred due to the need for novel method development. Given that their level of 
expression is similar to miRNAs, and as their functions become known, tRFs are 
expected to provide a new frontier in cancer biomarker development.   
tRFs have been characterized in RSV, HIV and HTLV-1 infection [109, 114, 
146]. A pyrosequencing study showed that a tRF derived from tRNA-Lys is increased in 
cells infected with HIV and that loss of this expression allows HIV replication [109]. A 
different tRF derived from tRNA-Pro was shown to be incorporated into HTLV-1 viral 
particles and shown to act as a primer for reverse transcriptase during replication [146]. 
The specificity of particular tRFs to viral regulation provide hope that these tRFs may 
eventually provide novel therapeutic targets to block viral infection.   
Oxidative stress results in tissue damage and is associated with many disease 
states.  A recent study has shown that even before DNA damage is detectable tRFs are 
detectable.  A specific RNA signature, tRNA-specific modified nucleoside 1-
methyladenosine (m1A), is detected in patients who have kidney damage and correlates 
with mortality [147]. Early detection of tissue damage would be helpful in the detection 
of many diseases, thus, the emerging field of tRFs provides potential for the discovery of 
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novel biomarkers aimed at earlier detection.  More study is needed to determine if tRFs 
will provide promising new candidates for future biomarkers of health and disease.    
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Chapter 2: A Method for Extracting and Characterizing RNA from Urine: for 
downstream PCR and RNAseq Analysis  
 
This chapter is adapted from published work:  
Zhou et al. A Method for Extracting and Characterizing RNA from Urine: for 
downstream PCR and RNAseq Analysis. Analytical Biochemistry, August 8th 2017. 
doi:10.1016/j.ab.2017.08.003. 
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Chapter Summary 
Readily accessible samples such as urine or blood are seemingly ideal for 
differentiating and stratifying patients; however, it has proven a daunting task to identify 
reliable biomarkers in such samples. ncRNA holds great promise as a source of 
biomarkers distinguishing physiologic wellbeing or illness. Current methods to isolate 
and characterize RNA molecules in urine are limited. In this proof of concept study, we 
present a method to extract and identify small ncRNAs in urine. Initially, qRT-PCR was 
applied to confirm the presence of miRNAs in total RNA extracted from urine.  Once the 
presence of miRNA in urine was confirmed, we developed a method to scale up RNA 
extraction to provide adequate amounts of RNA for next generation sequence analysis. 
The method described in this study is applicable to detecting a broad range of small 
ncRNAs in urine; thus, they have wide applicability for health and disease analyses. 
 
 
 
 
 
 
 
 
 
 
  34 
Introduction 
Physiologically representative and accessible samples such as saliva, blood or 
urine have long been expected to provide a source of biomarkers with high potential for 
characterizing conditions of health and disease.  These types of samples are referred to as 
liquid biopsies and may harbor circulating cells, protein, DNA, and RNA biomarkers 
[148].  RNA is one component within these samples that was initially ignored due to its 
propensity for rapid degradation by RNases.  However, with the identification of 
miRNAs and their notable stability in physiologic samples, RNA has come to the 
forefront of readily accessible molecules for the discovery of novel biomarkers [47, 149, 
150].   
ncRNAs found in liquid biopsies include, but are not limited to, rRNAs, tRNAs, 
tRFs and miRNAs. The wide variety of functions of extracellular ncRNAs are currently 
under investigation. For example, the tRFs, although having the unfortunate name of 
tRFs, are actively processed from mature tRNAs and their function is beginning to be 
elucidated [151].  While the miRNAs are already known to function in most if not all 
biological processes. Circulating miRNAs as serum biomarkers of health and disease 
have been robustly explored [152-154]; however, the miRNA repertoire in urine is less 
studied.  The majority of the early studies of RNA in urine were focused on prostate, 
bladder and kidney disease because these tissues would directly contribute extracellular 
vesicles (EVs) to urine [155, 156].   In many of the studies of EVs in urine, they are 
referred to as exosomes due to their size of approximately 40-100 nanometers. The term 
EV refers to any EV including but not limited to the microvesicles, ectosomes and 
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exosomes [141].  The misconception that exRNAs must be associated with EVs persists 
despite recent studies that show exRNAs may be associated with protein and lipid 
complexes independent of vesicles [157-159]. These findings suggest that exRNA in 
urine may provide useful biomarkers of physiological relevance to many diseases not 
limited to those involving urologic disease[160].   
Urine based biomarkers would be ideal for many studies because of the accessible 
nature of urine.  Urine is readily collected in many animal models, as well as in the 
veterinary setting and for human health assessment.  A urine based RNA biomarker for 
ovarian cancer would be particularly useful due to the inaccessible nature of the ovaries 
and the ability of this cancer to metastasize with few symptoms [17, 43, 44]. Studies of 
miRNAs in ovarian cancer have delineated a set of differentially expressed miRNAs that 
are expected to regulate key tumor suppressors such as BRCA1 [161].  Such oncomirs 
would be expected to be over expressed in biological fluids from cancer patients and have 
been studied in tissue, serum, ascites fluid and urine from ovarian cancer patients [71, 73, 
162-164]. miRNAs associated with EVs are also found in urine from healthy volunteers 
[165, 166].  It is possible to isolate EVs from large amounts of urine by a combined 
method of filtration and ultracentrifugation [165, 166]; however, a rapid method to isolate 
total RNA from small amounts of urine is needed.  In this article, we present a proof of 
concept study of the isolation of total RNA from urine allowing either qRT-PCR or RNA 
deep sequencing.    
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Results 
In order to identify the repertoire of ncRNAs in urine samples, we developed 
methods to obtain sufficient RNA for RNA deep sequencing.  The amount of total RNA 
obtained from a one hundred microliter aliquot of urine provided amplifiable RNA for 
qRT-PCR (Table 3), however, not enough RNA for RNA deep sequencing.  In order to 
collect adequate amounts of RNA for deep sequencing, one milliliter samples of urine 
were obtained from the Gynecologic Tissue and Fluid Bank (GTFB) at the University of 
Colorado and divided into 100 l aliquots.  Each aliquot was then stored at -80 oC with 
700 l of the phenol reagent, Qiazol, for at least one hour (Figure 4).  A final 
concentration step using low pH phenol was used to combine six samples into one, thus 
allowing for an increase in total RNA extracted from the same urine sample (Figure 4).  
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Table 3.  Total RNA was extracted from eight urine samples and analyzed by qRT-
PCR, bioanalysis and RNA deep sequencing.  The age, stage and histology for each 
patient sample is included. 
 
 
 
Sample 
#
Age, 
Stage
Histology
RNA Quality        
(Detectable RNA)
RNA 
Quality 
(RIN)
Total 
reads in 
millions
1 72, IIIC
 mucinous 
adenocarcinoma
RNU6B, miR-29a 2.5 2.6
2 63, IIIC high grade serous
RNU6B, miR-29a, 
miR-146a
2.2 49.6
3  48, IIIC high grade serous
RNU6B, miR-29a, 
miR-146a
2.6 6.2
4  67, IV high grade serous RNU6B 2.5 2.7
5  72, IV high grade serous RNU6B 1 1.6
6  57, IIIC high grade serous
RNU6B, miR-29a, 
miR-146a
2.5 5.8
7 48, IIC high grade serous RNU6B
Less than 
1.0 
4.8
8  72, IIIC high grade serous RNU6B 1.1 2.5
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Figure 4.  Suggested workflow for ncRNA extraction and analysis from urine 
obtained from patients or animal models. Notes of specific clarification (a-c) of the 
method are included in Table 4. 
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Table 4. Specific clarification of the methods in Figure 4.   
(a). Urine collection 
Urine that is collected during surgery from a catheterized patient may be stored 
unfiltered since it is considered to be sterile at the time of collection. It should be 
stored at -80 °C for long term storage. 
 
Urine that is from the method known as a clean capture in the human clinic and animal 
samples collected in a nonsterile manner will need to be filter sterilized using a 0.22 or 
0.45 micron filter prior to RNA extraction. Filtration before storage is required for 
samples that will be used for deep sequencing studies where many of the reads could 
come from bacterial contaminants depending on the method of collection and time 
before freezing of samples. A product known as a steriflip (MilliporeSigma, US) is 
especially useful for larger volumes of urine [167]. 
(b). Volume of urine required for RNA extraction 
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The miRNeasy kit from Qiagen requires the addition of 100 µl of urine to 700 µl of 
Qiazol.  Once the Qiazol product is added to the urine it may be stored indefinitely at -
80 °C.  We recommend storing it at -80 °C for at least one hour prior to processing.  
The theory is that the freeze thaw helps with the release of RNA from proteins or EVs 
in the urine. Specifically from Tamm-Horsfell protein networks a major confounder in 
isolation of either protein or nucleic acids from urine [168].   
 
The minimum volume that we have tested is 12 µls of urine and we have been able to 
generate amplifiable cDNA from RNA extracted with volumes ranging from 12 to 100 
µls of urine. It is recommended that the same volume of urine and the same method of 
collection be used for all samples in the same study. 
 
The Qiagen kit called miRNeasy (Cat No. /ID: 217004, Qiagen) is supplied with 
Qiazol, which is a phenol based reagent (use caution to avoid contact with skin).   
 
Use the protocol supplied by Qiagen with the following exceptions and reasoning:  
 
There is no need to do the optional DNAse digestion step for urine samples because 
there is very little contaminating DNA in this type of sample.  The miRNeasy kit is 
optimized for small RNAs less than 200 base pairs. 
 
An optional step of putting the spin column in a new 2ml tube is recommended in the 
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protocol. However, this is a required step in this urine protocol to prevent carry over of 
the final RPE buffer.  An additional change is that the final spin to dry the column is 
recommended as 1 minute in the Qiagen protocol and we suggest a three minute spin to 
be sure that the column is completely dry thereby preventing carry over of ethanol 
containing buffer that might interfere with downstream use.   
 
The use of the lowest recommended volume of RNase-free water to elute the RNA 
from the column (30 µls) is used in order to keep the extracted RNA as concentrated as 
possible. 
(c)  cDNA preparation and amplification to confirm RNA integrity 
The concentration of RNA obtained from 100 µls of urine is much lower than the 
expected accuracy range of the NanoDrop 1000. Although, the NanoDrop reading does 
confirm that there is RNA present in the sample.  Thus, we use the NanoDrop to 
confirm RNA extraction while not accepting the accuracy of concentration reading.  
Amplifiable RNA extraction and cDNA preparation are confirmed by a positive result 
for qRT-PCR of a small RNA compared to the cDNA water control.  The cDNA water 
control contains everything except RNA, which is required because it is known that the 
reagents present in cDNA kits and enzymes used for reverse transcription are routinely 
contaminated with exogenous RNA [169].   
 
The Miscript II kit (Qiagen) for reverse transcription is used with the maximum 
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volume, allowed by the kit, of 12µls of total RNA per sample. qRT-PCR was 
conducted using the miScript SYBR Green reagent (Qiagen) and custom primers were 
designed for the forward primer and specific to the RNA molecule to be amplified.   
 
The primer for miR-29a has an additional three C residues added to increase melting 
temperature in later steps. The actual melting temperature of miR-29 for qRT-PCR 
when it is not adapted is too low for the needed specificity (miR-29a-3p 5’-
cccTAGCACCATCTGAAATCGGTTA) and for miR-146a-5p (5’-ggT GAG AAC 
TGA ATT CCA TGG GTT) the melt temperature is increased by the addition of two 
bases.  
 
The RNU6B_13 primer from Qiagen is necessary because other variations of RNU6B 
primers do not routinely amplify extracellular U6. Other internal controls may be more 
suitable and should be tested for their consistency in the samples of interest [170]. 
 
RNA extracted from eight samples was first assessed for the presence of small 
RNAs by qRT-PCR for either U6, miR-29a or miR-146a.  If the sample were positive by 
qRT-PCR, the sample was then submitted for library preparation regardless of its RNA 
integrity number (RIN). Later, the total number of reads were compared across the eight 
samples and it was found that the total number of reads varied widely (Table 3).   
The libraries of ncRNAs in the urine from eight samples consisted of a wide range 
of RNA molecules including, but not limited to, rRNA, miRNAs and tRFs. The 
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combined deep sequencing results from all eight samples are shown in Figure 5A, which 
is derived from the total annotated reads of ncRNA and shown as the percent of miRNAs, 
tRFs and other ncRNAs for all libraries.  In Figure 5B the three categories are shown as 
percentage of total annotated reads in each individual library.   
  44 
 
  45 
Figure 5. Percentage of ncRNAs. Reads from urine are classified as miRNA, tRFs or 
other ncRNAs. (A) Total reads from 8 urine samples summarized by percent of reads 
from each sample, microRNAs (black), tRFs (light grey) and other noncoding RNAs 
(dark grey). (B) The percentage of reads for each individual sample again with 
microRNAs (black), tRFs (light grey) and other noncoding RNAs (dark grey). 
 
The overall repertoire of ncRNAs varied across samples, with a predominant 
number of reads falling into the “other ncRNAs” category, although one sample had a 
higher percentage of tRFs (Figure 5B, sample 2).  The percent of miRNAs varied widely 
from a few percent to more than 25% (Table 5).  To better understand the classification 
of ncRNA in the urine samples, we queried the eight samples for the five most highly 
expressed ncRNAs in each library and limited the analysis to those RNAs that were 
annotated in the GRCH37.57. ncRNA data base (Table 6).   
 
Table 5. Annotated Reads for overall ncRNAs. 
 
Patient 
Sample #
miRNA 
reads
tRF 
reads
ncRNA 
reads
miRNA 
percentage
tRF 
percentage
ncRNA 
percentage
total reads
1 105610 10521 347183 22.79% 2.27% 74.93% 463314
2 2060974 16058115 1363668 10.58% 82.42% 7.00% 19482757
3 444849 51460 1031958 29.11% 3.37% 67.52% 1528267
4 14208 10286 533617 2.55% 1.84% 95.61% 558111
5 7935 3062 125592 5.81% 2.24% 91.95% 136589
6 264617 210105 1989653 10.74% 8.53% 80.74% 2464375
7 11659 16257 532983 2.08% 2.90% 95.02% 560899
8 21564 14468 144149 11.97% 8.03% 80.00% 180181
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Table 6. The top 5 ncRNAs in each of the urine samples as determined by percent of 
total annotated reads. The Ensembl genome number from GRCH37.57. ncRNA is 
included as well as a sequence name when available. 
 
 
The most highly expressed small RNAs were generally fragments related to 
rRNAs and pseudo rRNAs. Very little is known about the function of extracellular 
rRNAs and pseudo rRNAs; however, they have been proposed to be processed in 
response to stress, including oxidative stress [76, 79].   
Among the ncRNAs, miRNAs are currently the most well studied group in urine.  
Overall analysis of the miRNAs in the eight samples revealed that miR-10b was by far 
the most highly expressed miRNA in all eight samples followed by miR-10a in five of 
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the eight samples. Other miRNAs that were second to the highest in at least one patient 
were miR-22 and miR-30a.  Interestingly, a miRNA often associated with oncogenesis, 
miR-21, was only in the top five in one sample (Table 7). 
 
Table 7. The top 5 miRNAs in each of the urine samples as determined by percent of 
total annotated reads.   
 
The most highly expressed miRNA in this study, miR-10b, is not well studied in 
ovarian cancer, although it has recently been implicated in metastasis in other cancer sites 
[171].  Based on a literature review we expected to find miR-146a and miR-29a in urine 
due to their previous association with ovarian cancer and previous findings of their 
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presence in exRNA samples [73, 163, 172, 173]. However, neither of these miRNAs 
were highly expressed in any of the eight samples as detected by small RNA deep 
sequencing.  
A large group of reads in the deep sequencing studies derived from tRNAs and 
belonged to the group of functional ncRNAs known as tRFs [174].   The small RNA 
reads in this study were mapped against the known human tRNAs using the GtRNAdb 
data base [175, 176]. The most highly expressed tRFs in the eight samples are reported in 
Table 8.   
 
Table 8. The top 5 tRFs in each of the urine samples as determined by percent of 
total annotated reads.   
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Highly expressed tRFs in the urine included the tRNA halves as well as a large 
number of variants differing by only a few bases. One tRF variant of the tRNA halve for 
tRNA-Glu-CTC (miR-2476) was of particular interest because it had been previously 
reported as a miRNA in the cow.  The miR-2476 had not been previously described in 
human samples; further, it has been removed from the miRNA data base because of its 
location near a tRNA, tRF5-Glu-CTC [177]. The tRF5-Glu-CTC variant that was 
previously called miR-2476 is missing a guanine at the sixth base (Table 9A, named 
tRF5-Glu 1Gv).  We examined several deep sequencing studies available at GenBank to 
determine if this variant of tRF5-Glu-CTC had been observed in other human studies.  
We queried the publicly available data for the presence of tRF5-Glu 1Gv as well as the 
most prevalent variant from our urine analysis called tRF5-Glu 2Gv (Table 9B).  One 
study of particular interest, where both variants were observed, was a comparison of the 
RNA cargo in exosomes isolated from the media of ovarian cancer cells, ovarian cancer 
associated adipocytes, normal adipocytes, cancer associated fibroblasts and normal 
fibroblasts [178]. 
 
Table 9. The expression of tRF5-Glu-CTC and its variants in urine and human 
samples. (A) The variants detected by small RNA deep sequencing in all eight urine 
samples. The average in all eight samples is given followed by the range of expression.  
The length in base pairs refers to the length of the variant. The entire length of tRNA-
Glu-CTC-1-1 is included for comparison. (B) The two most prevalent variants of tRF5-
Glu-CTC are presented here along with the SRA accession number and type of sample. 
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Table 9A 
 
Table 9B 
 
 
The variants of tRF5-Glu (both 1Gv and 2Gv) were found in all 13 samples, with 
2Gv being more highly expressed in most samples.  The increased expression of the 2Gv 
is similar to our finding in urine from ovarian cancer patients (Table 9A).  Both variants 
were highly expressed in cancer adipocytes as compared to the other samples.  The 
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ovarian carcinoma derived cell line A2780 had increased expression compared to the 
other three cell lines [179]. The top five tRFs from this study were also analyzed for their 
expression in data bases available at NCBI in the SRA collection (Table 10).  In this 
expanded analysis tRF5-Glu was by far the most highly expressed tRF from urinary 
exosomes. The use of publicly available data to verify the existence of specific variants 
of tRFs provides a readily available resource to the research community for follow-up 
studies of deep sequencing analysis.  Confirmation of variant expression by their 
presence in additional publicly available samples may guide the choice for further study 
of specific exRNAs.   
 
Table 10. Top five tRFs in publicly available SRA data sets. 
 
Accession 
number
tRF-Glu tRF-Gly tRF-Lys tRF-Val tRF-His
Total 
reads
Ovarian cancer cell line A2780 SRX1550574 1583 257 380 1 0 214630
Ovarian cancer cell line HeyA8 SRX1550575 184 130 108 4 1 281330
Ovarian cancer cell line OVCA433 SRX1550576 154 55 27 1 0 338204
Ovarian cancer cell line SKOV3 SRX1550577 33 12 15 1 0 256003
Ovarian cancer adipocytes OMT924007 SRX1550585
more than 
20,000
954 4851 137 14 461313
Ovarian cancer adipocytes OMT916645 SRX1550586 9821 128 730 62 4 234100
Cancer associated fibroblasts CAF866652 SRX1550580 1164 76 57 2 1 288787
Cancer associated fibroblasts CAF869881 SRX1550581 336 89 47 7 2 427929
Cancer associated fibroblasts CAF888242 SRX1550582 636 313 269 12 2 485258
Normal ovarian fibroblasts NOF151 SRX1550578 162 102 76 5 0 305013
Normal ovarian fibroblasts NOF81000 SRX1550579 308 134 203 5 0 324908
Normal omental adipocytes OMN050312 SRX1550583 1987 26 830 24 1 339618
Normal omental adipocytes OMN923075 SRX1550584 557 59 176 17 3 269810
Sequences used for BLAST analysis:
tRF-Glu (CCCTGGTGGTCTAGTGGTTAGGATTCGGCGC); tRF-Gly (CATTGGTGGTTCAGTGGTAGAATTCTCGCCT); 
tRF-Lys (CCCGGCTAGCTCAGTCGGTAGAGCATGGGAC);tRF-Val (CTTCTGTAGTGTAGTGGTtATCACGTTCGCCTC); 
tRF-His (CCGTGATCGTATAGTGGTtAGTACTCTGCGT)
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Discussion 
Liquid biopsies utilizing novel and robust ncRNA targets hold great potential for 
the development of new biomarkers [47, 180].  High throughput sequencing studies have 
fueled the search for novel ncRNA biomarkers from accessible samples including serum, 
plasma and urine [73, 150]. The unexpected stability of exRNA and new technologies to 
deep sequence RNA have led to an explosion of new biomarker studies focusing on 
ncRNAs in accessible samples [47, 148-150].   RNA is a preferred molecule for 
biomarker discovery in liquid biopsies due to its representation of the physiological state 
of the organism [180, 181]. RNA as a potential biomarker in urine was recognized as 
early as the 1970s when tRNAs were detected at increased levels in urine from cancer 
patients [182]. In these early studies, it was not possible to distinguish the specific 
ncRNA in urine, while it is now feasible with the advent of RNA deep sequencing 
technologies and the bioinformatics tools to analyze the vast amount of information. 
 Methods to extract exRNA from accessible samples are widely ranging and varied 
in the ability to capture amplifiable RNA [167].  It was initially thought that RNA was 
only stable in urine if it were protected as cargo in exosomes from bladder and urinary 
tract cells or from the kidney if there is damage.  Thus, studies of exRNA in urine 
exosomes were initially expected to favor the isolation of ncRNA from the bladder. 
However, it is now increasingly accepted that exRNA in urine can also come from other 
tissue sites as well as tumors [183-185]. 
Many of the recent studies aimed at identifying exRNA in urine through deep 
sequencing protocols are focused on the ncRNA found in EVs and including the subset of 
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EVs known as exosomes [167].   The extraction of RNA from urinary EVs requires a 
large volume of urine to ensure that enough RNA will be extracted for downstream 
applications. The suggested volume of urine for RNA deep sequencing biomarker 
discovery protocols ranges anywhere from 5mls to 250mls of urine [165-167, 186].  
Furthermore, the collection of exosomes requires either ultracentrifugation or treatment 
with a proprietary method such as the Exosome RNA Isolation kit from Norgen (Norgen 
Biotek Corporation, Thorold, ON, Canada) to concentrate the exosomes [186]. Studies of 
the repertoire of exRNA associated with EVs and specifically exosomal RNA provide a 
partial understanding of the exRNA present in urine.  Methods to extract total RNA from 
urine are also needed.   
Methods designed to conduct RNA deep sequencing on total RNA extracted from 
urine are less common than exosomal studies. One such study of total RNA extracted 
from the urine of male goats utilized 500µl samples successfully to accomplish deep 
sequencing [187]. Other studies based on the extraction of total RNA from a small 
volume of urine did not attempt deep sequencing, rather these methods were used for 
miRNA Array studies or qRT-PCR and required as little as 50µls for analysis [188].  The 
methods we describe in this article require similar volumes of urine and allow the 
isolation and analysis of total RNA by both qRT-PCR and small RNA deep sequencing.  
Once biomarkers are discovered in pilot studies such as these, it will be possible to scale 
up to larger studies and develop methods with direct clinical utility. 
 In order to determine the full spectrum of exRNA in urine, patient samples were 
requested from the GTFB at the University of Colorado.  These samples had been 
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obtained with informed consent and had all been collected during surgery and handled in 
a consistent manner prior to storage at -80 oC. Consistent collection and storage of 
samples is required for all studies of exRNA and the importance of collection and storage 
has been described previously [189, 190]. Ovarian cancer is a very difficult disease to 
detect and frequently is found at late stage; thus, one goal of the GTFB is to provide a 
resource for studies to discover new biomarkers for patient care.  In this pilot study, we 
analyzed the miRNAs and tRFs and grouped the rRNA fragments with all other ncRNAs 
(Figure 5).  The total tRFs, miRNAs and other ncRNAs were first analyzed for all 
samples by percent of total annotated reads. Combining the reads from all samples gives 
an overview of the types of RNAs in ovarian cancer patient urine (Figure 5A).  However, 
the grouping of all reads is misleading as individual samples were very different from 
each other (Figure 5B).  The variability of classes of RNA in patient samples suggests a 
potential to discover unique biomarkers in urine.  Although this proof of concept project 
provides methods to identify biomarkers in urine, a larger study with the goal of 
discovering specific biomarkers for ovarian cancer patients will be required.   
 The top five most highly expressed exRNAs in most samples were dominated by 
the group of other ncRNAs; however, miR-10b, miR-10a and miR-30a were also found 
in this group (Table 6).  The predominant miRNA was by far miR-10b, which was the 
top miRNA in all samples (Table 7).  miR-10a was also one of the top five in all samples 
and in many samples miR-22 and miR-30a were frequently observed.  miR-21, a miRNA 
reported to be highly expressed in cancer patients, was only observed among the top five 
molecules in one sample (Table 7). Although the goal of this pilot study was to develop 
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methods to study RNA biomarkers in patient urine, it will be interesting in future studies 
to determine if there is a role for miR-10a and 10b in ovarian cancer.  A literature review 
revealed that few previous studies of miR-10 in ovarian cancer have been conducted.  
However, the role of miR-10 has been elucidated in normal granulosa cells of the ovary 
and is linked to feedback regulation of the TGF-β signaling pathway [191]. We also 
observed the presence of miR-10a and 10b in publicly available data of normal 
fibroblasts and cancer associated fibroblasts, where the miR-10 family was equally 
expressed in both normal and cancer associated fibroblasts [178]. A group of miRNAs 
expressed in ovarian cancer has been suggested to form a signature predictive of poor 
outcome in ovarian cancer patients [192]; however, the only miRNA included in that 
signature that is also detected in the top five miRNAs in this study was miR-30d (Table 
7).  The role of miRNAs in ovarian cancer is still being investigated as is the role of tRFs. 
These exRNAs are expected to provide new physiologically relevant biomarkers for 
ovarian cancer. 
exRNA contains a complex variety of ncRNAs, including numerous tRFs and 
their variants whose complexity is just now being realized [79, 85, 111, 145, 193].  The 
complexity of tRF expression is in part due to the frequent modification of nucleosides in 
the mature tRNA, which may interfere with tRF detection in high-throughput sequencing 
studies [80]. In addition to high throughput sequencing, additional methods including 
qRT-PCR and Northern analysis are routinely used to identify tRFs. However, tRFs are 
derived from pre- and mature tRNAs making them difficult to distinguish by established 
assays. Honda et al. have developed methods to specifically analyze tRFs using ligation 
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PCR [89].  Future studies aimed at applying tRFs as biomarkers in patient samples will 
require the development of methods specific to tRFs. 
In order to confirm the use of deep sequencing of RNA from urine as a potential 
method of discovering new biomarkers, we chose one tRF, tRF5-Glu-CTC, for further 
study.  We examined publicly available databases of exRNA isolated from exosomes to 
determine if tRF5-Glu and its variants are detectable in exRNA from EVs (Table 9B).  
Libraries of exRNA isolated from exosomes obtained from ovarian cancer cell lines, 
cancer associated adipocytes, normal adipocytes, cancer associated fibroblasts and 
normal fibroblasts were queried for the presence of tRF5-Glu-CTC [178]. The 
predominant variants from the urine samples were also detected in the RNA from 
exosomes (Table 9). The use of publicly available data to confirm the expression of 
previously unidentified exRNAs provides an additional resource to study the numerous 
exRNAs in urine. The methods described here are readily adapted to other species and 
other disease conditions for the future development of physiologically relevant urine 
based biomarkers. 
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Experimental Materials and Methods 
 
Participants and Sample Collection 
The GTFB, at the University of Colorado Anschutz Medical Campus, collected 
urine from women undergoing gynecologic surgery. Urine was obtained from women 
with ovarian cancer under an IRB approved protocol (COMIRB Protocol 11-0626). 
Samples were provided as 1 ml aliquots of urine with information on patient age, stage 
and histology of the ovarian cancer.  Urine samples were collected during surgery and 
centrifuged prior to freezing at -80 oC for long term storage.  All samples were de-
identified and data was analyzed under a second IRB approved protocol at the University 
of Minnesota (study number: 1610E97724).   
 
RNA extraction and qRT-PCR analysis of miRNA 
Urine was defrosted once and aliquoted in 100µl aliquots and refrozen following 
the addition of 700µl of Qiazol Reagent (Qiagen, Valencia, CA). Total RNA was isolated 
from 100µl of urine using the miRNeasy Mini Kit (Qiagen).  The isolation procedure 
followed the miRNeasy protocol with a few clarifications explained in more detail in 
Table 4. The final elution volume for total RNA from the spin column was the minimum 
required, 30µl RNase free water, to allow the maximum concentration of RNA per µl for 
downstream applications. The concentration and quality of extracted RNA were assessed 
by spectrophotometry on the NanoDrop 1000 (Thermo Scientific, Waltham, MA). 
However, the concentration of RNA obtained is much lower than the expected accuracy 
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for the NanoDrop 1000; thus, in the following steps, we ignored concentration estimates 
and simply used the maximum template volume allowed in the protocol. For example, in 
the Miscript II kit (Qiagen) for a 20µl reaction it is possible to reverse transcribe a 
volume of 12µls of total RNA for cDNA preparation.  Amplifiable RNA extraction and 
cDNA preparation were confirmed by a positive result for qRT-PCR of a small RNA 
compared to the cDNA water control. qRT-PCR was conducted using the miScript SYBR 
Green reagent (Qiagen) with a custom primer for miR-29a-3p 5’-
cccTAGCACCATCTGAAATCGGTTA or miR-146a-5p 5’-ggT GAG AAC TGA ATT 
CCA TGG GTT.  We also used the RNU6B primer available from Qiagen for qRT-PCR 
assays (RNU6B_13).  Although in this study, we did not use an internal control for 
calibration of qRT-PCR results, it is important to mention that an appropriate internal 
control for exRNA studies is currently controversial.  Several helpful studies have 
examined this controversy and may be of use to those working in this field [170, 186, 
194].   
 
RNA precipitation, RNA quality assessment and Illumina Mi-seq methods 
Urine is a complex liquid containing EVs, protein, nucleic acids and many other 
metabolites [195].  Tamm-Horsfell is a protein in urine that is known to form networks 
that trap EVs [168]. In the study presented here we extracted RNA from six 100µl 
aliquots of urine and then combined these in the following step to reduce the 
concentration of contaminating substances such as Tamm-Horsfell protein. Total RNA 
from 600µl of urine (in 100µl aliquots) was extracted using the above protocol. The 30µl 
  59 
aliquots of purified RNA were combined into 1 tube for a total of 180 µls. This was 
extracted with addition of GenElute LPA as described by the manufacturer (Sigma-
Aldrich, St. Louis, MO) as previously described [196].  The use of LPA as a carrier is 
required because alternatives such as glycogen or yeast tRNA are isolated from biological 
sources and maybe contaminated with small ncRNA [196].  After LPA addition, the 
samples were extracted with low pH phenol (Ambion 9710) and chloroform:isoamyl 
alcohol (49:1) with a standard ethanol precipitation using 3M NaAcetate pH 5.2 (Table 
11).  
 
Table 11. Protocols for combining extracted RNAs for small RNA deep sequencing. 
Concentrating fractions of small RNA (Protocol ) 
1. First extract RNA from six 100 µl samples of urine, this is important rather than 
drying down a 600 µl sample because it reduces some of the protein contamination. By 
using more dilute samples and then recombining, we avoid some of the protein 
contamination [168].  
2. Combine six samples (180 µl of total RNA) then add 400 µl of low pH phenol 
(Ambion 9710) and 130 µl of CHCl3 (chloroform 49:1 with isoamyl alcohol) mix and 
spin at 13,200 rpm (Centrifuge 5415, Eppendorf) and collect supernatant. 
3. Add 0.75 µL LPA (GenElute, Sigma-56575, Sigma-Aldrich) (In many protocols, 
glycogen is often used as a carrier for nucleic acid percipitation. However, we and 
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others find LPA as the preferable carrier because Glycogen is a natural product and for 
that reason it may be contaminated with RNA or DNA [196]).  
4. Add 50 µl of 3M sodium acetate, pH 5.2 and 1 ml of 1:1 ethanol:isopropanol, 
precipitate over night at -80 ºC. 
5. Centrifuge samples for 20min at 4°C at 14000 rpm (Centrifuge 5417R, Eppendorf) 
6. Remove supernatant with a pipet, being careful to avoid dislodging the RNA pellet 
7. Wash pellet with 500 µL 70% ethanol  
8. Centrifuge samples for 15min at 4°C at 14000 rpm to reseat the pellet 
9. Remove supernatant as quickly as possible as the pellet can become slippery in 70% 
ethanol 
10. Air dry samples and resuspend in nuclease free water. *do not over dry samples 
11. Store at -80°C and submit for library construction (next day) 
 
 
Library preparation and Illumina sequencing analysis  
RNA was forwarded to the UCD Genomics and Microarray Core for library 
construction. In the core facilities, RNA was assessed for quality on the Agilent 
Bioanalyzer 2100 using the Eukaryote Total RNA Pico Chip (Agilent Technol., Palo 
Alto, CA). RNA libraries were constructed using a volume of 5µls of total RNA rather 
than the recommended concentration of RNA need to prepare the Illumina HiSeq 
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libraries. The TruSeq Small RNA kit uses a 3ʹ adapter modified to target miRNAs and 
other small RNAs that have a 3ʹ hydroxyl group. Enriching for RNA with a 3’hydroxyl 
allows the detection of RNA that has been enzymatically cleaved by Dicer or other RNA 
processing enzymes.  Small RNA template libraries were sequenced using small RNA 
deep sequencing technology on the Illumina HiSeq2000 platform at the University of 
Colorado’s Genomics and Sequencing Core Facility.   
 
miR-seq data analysis 
The miRNA sequence reads were identified for known and novel miRNA 
sequences using the program miRDeep. We calculated the expression of the miRNA 
variants based on normalized read counts and tested for significant differences using 
ANOVA in R. Galaxy cutadapt was used for each fastq file to remove adapters. Then 
fastq files were imported into CLC Genomics workbench to identify and count unique 
small RNAs using two databases as reference (miRBase Release 19 and Homo sapiens 
GRCh37.57 ncRNA). The individual data files of trimmed reads have been uploaded to 
the publicly available data base at https://doi.org/10.5281/zenodo.801484.   
Additional data sets were searched from publicly available data at NCBI on the 
SRA website [178]. 
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Chapter 3: A tRNA Fragment, tRF5-Glu, Regulates BCAR3 Expression and 
Proliferation in Ovarian Cancer Cells 
 
 
This chapter is adapted from published work:  
Zhou et al. A tRNA Fragment, tRF5-Glu, Regulates BCAR3 Expression and Proliferation 
in Ovarian Cancer Cells. Oncotarget, Sept 8th 2017. doi: 10.18632/oncotarget.20709. 
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Chapter Summary 
 
Ovarian cancer is a complex disease marked by tumor heterogeneity, which 
contributes to difficulties in diagnosis and treatment.  New molecular targets and better 
molecular profiles defining subsets of patients are needed. tRFs offer a recently identified 
group of ncRNAs that are often as abundant as miRNAs in cancer cells.  Initially their 
presence in deep sequencing data sets was attributed to the breakdown of mature tRNAs, 
however, it is now clear that they are actively generated and function in multiple 
regulatory events. One such tRF, tRF5-Glu, is processed from the mature tRNA-Glu and 
is shown in this study to be expressed in ovarian cancer cells. We confirmed that tRF5-
Glu binds directly to a site in the 3’UTR of BCAR3 mRNA thereby down regulating its 
expression. BCAR3 has not previously been studied in ovarian cancer cells and our 
studies demonstrate that inhibiting BCAR3 expression suppresses ovarian cancer cell 
proliferation. Furthermore, mimics of tRF5-Glu were found to inhibit proliferation of 
ovarian cancer cells.  In summary, BCAR3 and tRF5-Glu contribute to the complex 
tumor heterogeneity of ovarian cancer cells and may provide new targets for therapeutic 
intervention.   
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Introduction 
Worldwide, ovarian cancer is a leading cause of cancer mortality among women, 
with the five-year survival rate for women with advanced stage disease expected to be 
less than 30% [17].  The poor survival is attributed to several factors including 
nonspecific symptoms of early disease, late stage of diagnosis, and the molecular 
heterogeneity of the disease [17, 43].  A recent summary and review of microarray 
studies of tissue samples from ovarian cancer patients demonstrates that heterogeneity is 
associated with the wide diversity of patient outcomes [44].  In addition to the molecular 
heterogeneity of mRNA expression, it is now being realized that regulation by ncRNAs 
contributes to the diversity of gene expression in cancer patients [197, 198].  
The impact of newly identified regulatory mechanisms of small ncRNAs on the 
heterogeneity of gene expression in cancer is exemplified by the recent explosion of 
miRNA studies including their expression in ovarian cancer [52, 162, 164, 199].   
Furthermore, due to an increase in studies utilizing high throughput sequencing 
technologies even more prevalent classes of ncRNA are being identified [77, 200].  One 
group of recently identified ncRNAs implicated in cancer biology are the tRFs [85, 174, 
201].   tRFs are evolutionarily conserved, from prokaryotes to eukaryotes, and include 
segments of tRNAs from both pre-tRNAs and mature tRNAs [77].  Due to their recent 
identification, the naming convention for members of the tRFs is not yet consistent [85, 
92, 145].  The tRFs as a class include but are not limited to tRNA halves, tiRNAs, 
tsRNAs, intermediate tRFs, 5’tRFs, 3’tRFs, and SHOT-RNAs [82, 84, 86, 88, 89].  
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The biogenesis of tRFs is an active process resulting from the cleavage of tRNAs 
by multiple enzymes including ANG, RNase Z, and Dicer [82, 84, 88]. The potential 
functions of tRFs are the focus of many current studies.  tRFs have been isolated as part 
of AGO complexes implying that one function of a subset of tRFs may be similar to that 
of miRNAs [129, 201, 202]. For instance studies initially aimed at identifying miRNA 
targets , including high-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation (HITS-CLIP), photoactivatable ribonucleoside-enhanced 
crosslinking and immunoprecipitation (PAR-CLIP) and crosslinking, ligation and 
sequencing of hybrids (CLASH) studies, have been reanalyzed to confirm the association 
of tRFs with mRNAs from numerous cellular sources, including a subset from cancer cell 
lines [129, 145, 193, 201].  An association with AGO implies that tRFs may be regulators 
of mRNA expression.  To date, however, only a few direct mRNA targets of tRFs have 
been confirmed [129, 203].   
A subset of tRFs were initially misclassified as miRNAs and were eventually 
discovered and eliminated from miRBase if their genomic location was near or embedded 
in a tRNA gene [75, 204].  For example, miR-2476, which is one base pair different from 
the 5’-tRF derived from tRNA-Glu-CTC, was discovered in the cow and pig and is now 
called a dead entry because of its location near a known tRNA (miRBase Accession: 
MI0011537) [177].  Prior to its elimination from miRBase, miR-2476 was included in 
TargetScan (6.2) for the cow and predicted to bind the 3’ untranslated region (UTR) of 
many potential mRNA targets. In a pilot study, we found that tRF5-Glu is present in the 
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urine of ovarian cancer patients (Chapter 2) and questioned if it might be present in 
ovarian cancer cells. 
In order to determine if tRF5-Glu is expressed and functional in ovarian cancer 
cells, we examined its expression in five ovarian cancer cell lines. We have shown that 
tRF5-Glu is present in ovarian cancer cells grown in culture and is capable of directly 
binding a predicted target BCAR3. BCAR3 has been well studied in breast cancer for its 
role in anti-estrogen resistance and breast cancer cell proliferation [205]. BCAR3 is also 
known to be expressed in B cells, colorectal cancer, and more recently has been shown to 
function during development [206-209]. However, regulatory mechanisms governing the 
expression of BCAR3 remain poorly understood. The aim of this study was to identify 
the expression pattern, function and regulation of BCAR3 and tRF5-Glu in ovarian 
cancer cells.  In this study, we show decreasing BCAR3 expression and increasing tRF5-
Glu inhibits the proliferation of ovarian cancer cells. These studies begin to define the 
regulatory mechanisms of tRFs in ovarian cancer, providing a potential new class of 
molecules to target for therapeutic development.   
 
 
 
 
 
 
 
  67 
Results 
 
tRF5-Glu is expressed in ovarian cancer cell lines 
In order to confirm that ovarian cancer cells express tRF5-Glu, we interrogated a 
panel of ovarian cancer cell lines by qRT-PCR and Northern analysis.  The five ovarian 
cancer cell lines included PEO1, PEO4, SKOV3, 2008, OVCAR3 and were chosen for 
their molecular heterogeneity and previous use in studies of ovarian cancer [210-212].  
The cell line HEK293T was used as a positive control because the expression of tRF5-
Glu in this cell line had been previously described in RNA sequencing studies [202].  
Expression of tRF5-Glu was measured by qRT-PCR in these cell lines (Figure 6A).   
Northern Blot analysis provided further confirmation that tRF5-Glu is expressed in 
ovarian cancer cells (Figure 6B). 
 The ovarian cancer cell lines and HEK293T expressed tRNA-Glu and tRF5-Glu 
variants.  The full length mature tRNA-Glu is visible as larger than 70 nucleotides as 
expected.  The tRF5-Glu variants range in size from 29-35 nucleotides (Figure 6B, box).  
Models of the mature tRNA and the tRFs are included next to the corresponding bands of 
the Northern analysis (Figure 6B). The Northern analysis revealed that the ovarian 
cancer cell lines were able to express tRF5-Glu.    
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Figure 6. tRF5-Glu is expressed in ovarian cancer cell lines and HEK293T cells.  
Ovarian cancer cells were grown to confluence and lysed in passive lysis buffer for 
fifteen minutes prior to RNA extraction. (A) tRF5-Glu expression was assessed using 
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qRT-PCR. tRF5-Glu expression is shown relative to the expression of the internal 
control, RNU6B (U6).  qRT-PCR experiments are replicates of three independent 
experiments and error bars refer to +/- standard error.  (B) Validation of tRF5-Glu 
expression by Northern blot analysis. Northern analysis utilized a 5’ biotinylated probe 
designed to hybridize antisense to the tRF5-Glu region of tRNA-Glu. This probe binds 
unprocessed tRNA-Glu (greater than 80 base pairs), mature tRNA-Glu (70-80 base pairs) 
and tRF5-Glu (29-35 base pairs, box).   A schematic of the mature tRNA-Glu and the 
tRF5-Glu is included next to the northern blot showing the mature tRNA-Glu (top) and 
predominant cleavage sites for tRF5-Glu (bottom).  Potential cleavage sites resulting in 
various size fragments are shown with arrowheads on the schematic of tRF5-Glu.  
Ethidium bromide stained 5S rRNA below the blot serves as a loading control for the 
Northern analysis. 
 
ANG modulates the biogenesis of tRF5-Glu in ovarian cancer cells 
ANG is an RNase implicated in the biogenesis of the class of tRFs known as the 
tRNA-halves and the tiRNAs [87, 88]. The tRFs observed by northern blot correspond to 
the size expected for tRNA-halves. We performed RNAi knockdown of ANG expression 
in ovarian cancer cell lines to determine if ANG has a role in generating tRF5-Glu in 
ovarian cancer cells. Two ANG siRNAs were shown to significantly reduce ANG protein 
expression as compared with a control siRNA in the cell lines (Figure 7).   
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Figure 7. Western analysis of ANG protein expression following 48 hours treatment 
with control siRNA (con si) and ANG siRNAs (ANG si1, 2) in five ovarian cancer 
cell lines. Densitometry of each band was measured and the relative ratio of ANG/β-
Actin is shown. 
 
tRF5-Glu is part of the mature tRNA-Glu and it is not possible to accurately 
measure the fragment by routine qRT-PCR without also amplifying the mature tRNA. In 
order to accurately quantify tRF5-Glu using qRT-PCR methods, we modified an assay 
previously described by Honda et al., [89] (Figure 8A). The modified method is called 
ligation PCR and includes an internal control of U6 and a specific primer for tRF5-Glu. 
Ligation PCR confirmed that the tRNA half, tRF5-Glu, is reduced in all five cell lines 
treated with ANG siRNA (Figure 8B). We also confirmed changes in tRF5-Glu by 
Northern analysis in two cell lines treated with siRNAs to ANG (Figure 8C). The 
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loading control of 5S rRNA was used to show equal loading and we did observe a 
reduction in the mature tRNA-Glu, as has been shown in a recent study of another tRF 
[151]. Taken together ligation PCR and Northern analysis confirm that ANG participates 
in the biogenesis of tRF5-Glu in ovarian cancer cells.  
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Figure 8. The biogenesis of tRF5-Glu is regulated by ANG in ovarian cancer cells. 
ANG expression was blocked by transfection of cells with ANG siRNA to determine if 
tRF5-Glu expression is altered. (A) Ligation PCR provides a method to quantify tRF5-
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Glu, a diagram of the primer placement for Ligation PCR is included.  A labeled probe 
covering the junction between the end of the 3’ linker and target sequence is shown.  The 
linker is designated in grey, the cross junction probe has a star and arrows designate the 
primers. (B) Ligation PCR of cDNA from PEO1, PEO4, SKOV3, 2008, and OVCAR3 
cells transfected with control and ANG siRNAs was conducted. tRF5-Glu expression is 
compared relative to the internal control U6.  Ligation PCR experiments are replicates of 
three independent experiments and error bars refer to +/- standard error (* p-value <.05). 
(C) Northern analysis of RNA collected from cells transfected with a control siRNA and 
two ANG specific siRNAs (ANG siRNA1 and ANG siRNA2). The tRF5-Glu bands are 
shown within a box. 
 
tRF5-Glu and its predicted target BCAR3 are simultaneously expressed in ovarian 
cancer cells 
A variant of tRF5-Glu was previously misreported to be miR-2476 (miRBase 
accession number: MI0011537).  miR-2476, now recognized as a variant of tRF5-Glu, 
was included in TargetScan version 6.2 and thus a list of potential mRNA targets for 
miR-2476 is available. A somewhat controversial question about tRFs is if they function 
in a manner similar to miRNAs. We examined the list of predicted targets of miR-2476 in 
TargetScan 6.2 (available at http://www.targetscan.org/vert_61/) and selected potential 
targets for further analysis based on their previous expression in cancer (Table 12).  
 
Table 12. Potential targets of miR-2476 expressing in cancer cells [213-220]. 
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Targets of miR-2476 with a previous 
association with cancer. 
TargetScan 6.2 
(http://www.targetscan.org/vert_61/) 
Total 
Context+ 
score 
Previous studies in 
cancer for each of 
the top genes. 
Selected 
for 
further 
study 
CBX5 (HP1α)  
-0.78 
Regulated by an 
epigenetic 
methylation 
 
No 
 
PCGF2 (Mel-18) 
 
-0.63 
The 3’ untranslated 
region was shown to 
be associated with 
tumor suppression 
 
No 
 
CUX1 (CUTL1) 
 
 
-0.52 
Not the gene 
associated with 
ovarian cancer at 
7q22 
 
No 
 
BCAR3 
 
 
-0.50 
Associated with anti-
estrogen resistance 
in breast cancer 
 
Yes 
 
TCF20 (SPBP) 
 
 
-0.43 
Associated with anti-
estrogen resistance 
in breast cancer 
 
No 
 
CNTN2 (Tag-1) 
 
 
-0.41 
Early studies mostly 
in neuronal tumors 
 
No 
 
HIF3A 
 
-0.41 Not as much 
reported about 
HIF3A as about 
HIF1 or HIF2 could 
be interesting in 
future studies 
 
No 
 
FLT1 
 
-0.41 This is becoming 
significant in ovarian 
cancer but at the 
time these studies 
were initiated it was 
not as well studied 
 
No 
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 BCAR3 was selected from the genes predicted for regulation due to its expression 
in the ovarian cancer intraperitoneal xenograft model previously published and available 
from GEO Profiles (GDS4066:204032) [210]. The available GEO data indicates that both 
PEO4 and 2008 cells express the mRNA of BCAR3. In order for BCAR3 mRNA to be 
targeted by tRF5-Glu, they both must be present in cells grown under the same 
conditions.  To determine if BCAR3 and tRF5-Glu are present in ovarian cancer cells, 
PEO4 and 2008 cells were grown in the presence or absence of estrogen for 48 hours, 
similar to methods used in the GEO experiment [210]. 
 PEO4 and 2008 cells were both shown to express BCAR3 as well as tRF5-Glu 
under both growth conditions. Interestingly, BCAR3 expression decreased in estrogen 
stimulated PEO4 cells compared to estrogen starved PEO4 cells. However, there was no 
significant difference in BCAR3 expression between estrogen treated or estrogen 
deprived 2008 cells (Figure 9A and 9B).  In contrast, tRF5-Glu expression was increased 
in the PEO4 cell line stimulated with estrogen, while again no change was observed in 
the 2008 cell line (Figure 9C and 9D, box). These data demonstrate a potential 
correlation between BCAR3 and tRF5-Glu under estrogen stimulated growth conditions 
in PEO4, while no significant change in BCAR3 or tRF5-Glu was observed in 2008 cells. 
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Figure 9. tRF5-Glu and its potential target BCAR3 are expressed in ovarian cancer 
cell lines. Ovarian cancer cell lines were grown under estrogen starved (NE) or estrogen 
stimulated (E) conditions to determine the best conditions to study the potential 
relationship between tRF5-Glu and BCAR3. (A) Expression of BCAR3 mRNA in cDNA 
  77 
from PEO4 and 2008 cells estrogen starved (NE) or estrogen stimulated (E) as assayed by 
qRT-PCR. qRT-PCR experiments are replicates of three independent experiments and 
error bars refer to +/- standard error (*** p-value<.005). (B) Western analysis of BCAR3 
protein expression at 48 hours of estrogen starvation (NE) or estrogen stimulation (E) in 
the two ovarian cancer cell lines. Densitometry of each band was measured and the 
relative ratio of BCAR3/-Actin is shown. (C) Expression of tRF5-Glu amplified from 
cDNA of PEO4 and 2008 cells estrogen starved (NE) or estrogen stimulated (E) as 
assayed by ligation PCR.  (D) Northern analysis of tRF5-Glu in estrogen starved (NE) or 
estrogen stimulated (E) PEO4 and 2008 cells. Cells were grown for 48 hours in estrogen 
depleted media and then the media was replaced by new estrogen depleted media (NE) or 
media supplemented with estrogen for an additional 48 hours (E). Cells were then lysed 
by direct addition of Qiazol for RNA extraction. The tRF5-Glu bands are shown within a 
box. 
 
tRF5-Glu directly binds BCAR3 mRNA in ovarian cancer cells  
In order to confirm direct binding of the 3’UTR of BCAR3 by tRF5-Glu we 
modified the previously described miR-Catch assay [221].  We used a biotinylated probe 
targeting a region of BCAR3 predicted to have an open secondary structure upon RNA 
folding and distal to the predicted binding site for tRF5-Glu (Figure 10A). Cell lysates 
from PEO4 cells treated with estrogen for 48 hours were used because we had previously 
observed regulation of BCAR3 expression in this cell line with these growth conditions 
(Figure 9). Lysates were collected and hybridized to a BCAR3 specific biotinylated 
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capture probe or a random probe (Figure 10B).  BCAR3 mRNA was enriched by 
pulldown with a BCAR3 probe while it was not enriched by pulldown with a randomized 
probe.  Pulldown with a BCAR3 specific probe showed enrichment for tRF5-Glu.  
  To investigate if there is direct regulation of BCAR3 by tRF5-Glu, comparable to 
that expected of a miRNA, a reporter binding assay placing the 3’UTR of BCAR3 
downstream of the luciferase reporter was developed. Another reporter construct with 
two mutations in the predicted binding site was also generated (Figure 10C).  HEK293T, 
PEO4 and 2008 cells were transfected with these constructs in the presence of either a 
control or a specific mimic of tRF5-Glu. Forty-eight hours after transfection there was a 
significant 40% and 30% reduction in luciferase activity with the wildtype construct as 
compared to control in HEK293T and PEO4, respectively. A significant reduction in 
luciferase activity was not observed in 2008 cells (Figure 10D).  There was no 
significant reduction in luciferase activity with the luciferase assay containing mutations 
in the predicted miR-2476/tRF5-Glu binding site in HEK293T, PEO4 or 2008 (Figure 
10D). These results confirm that BCAR3 is directly regulated by tRF5-Glu.  However, 
the lack of response to tRF5-Glu mimics in 2008 cells suggests an alternative mechanism 
of BCAR3 regulation in this cell line. 
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Figure 10. Binding of the BCAR3 mRNA by tRF5-Glu is demonstrated using miR-
Catch and luciferase assays. (A) Secondary structure of the BCAR3 mRNA with 
placement of the DNA capture probe in relationship to the tRF5-Glu binding site is 
shown with arrows.  (B) Triplicate samples of PEO4 cell lysates probed with either 
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BCAR3 or a random probe were amplified by reverse transcription PCR (RT-PCR) for 
BCAR3 and tRF5-Glu expression.  The BCAR3 mRNA in the flow-through was 
amplified and is shown for each sample.   (C) A schematic of the BCAR3 3’UTR and 
predicted binding site for tRF5-Glu is shown with the wild type and mutant seed 
sequences listed below. Luciferase reporter plasmids were constructed containing the 
predicted binding site intact or mutated at two base pairs within the predicted seed region 
(designated by underlined letters). (D) Luciferase constructs with the wild type or mutant 
BCAR3 3’UTR were transfected into HEK293T, PEO4 and 2008 cells with a control 
mimic or a mimic of tRF5-Glu.  Transfections were performed in triplicate. The result 
was compared to a control mimic and error bars refer to +/- standard error (* p-value <.05 
and **** p-value <.001). 
 
tRF5-Glu directly regulates BCAR3 expression in ovarian cancer cells 
Further investigation of the regulation of BCAR3 by tRF5-Glu was studied in five 
cell lines, PEO1, PEO4, SKOV3, 2008, and OVCAR3 under growth conditions where 
BCAR3 was readily expressed.  All five ovarian cancer cell lines were transfected with 
control mimics and inhibitors or a tRF5-Glu specific mimic or inhibitor.  Western 
analysis for BCAR3 protein expression was conducted on cell lysates following 48 hours 
of treatment (Figure 11A).  
In response to treatment with a mimic of tRF5-Glu, BCAR3 expression was 
observed to decrease in PEO1, PEO4 and OVCAR3 cells as compared to a control 
mimic; however, in SKOV3 and 2008 cells, BCAR3 protein expression remained 
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unchanged. PEO1, PEO4 and OVCAR3 cells also increased expression of BCAR3 after 
receiving an inhibitor of tRF5-Glu compared to a control, whereas BCAR3 expression in 
SKOV3 and 2008 cells was unaltered.  
In order to further explore the regulation of BCAR3 by tRF5-Glu we constructed 
vectors expressing only a 50 base pair region of the 3’ UTR of BCAR3 (Figure 11B).  
The wild type and mutant constructs were transfected into HEK293T, PEO4 and 2008 
cells (Figure 11C).  When the smaller region of the BCAR3 UTR is included in the 
luciferase construct, regulation through the predicted binding site is possible regardless of 
the cell line where the luciferase constructs are expressed.  These results suggest that 
other regions of the BCAR3 UTR are required for the lack of regulation of BCAR3 by 
tRF5-Glu observed in 2008 cells.   
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Figure 11. Direct regulation of BCAR3 by tRF5-Glu is predicted in TargetScan 6.2 
which shows a binding site for miR-2476/tRF5-Glu in the BCAR3 3’UTR. Mimics 
and inhibitors of tRF5-Glu were used to determine if BCAR3 is regulated by tRF5-Glu.  
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(A) Western analysis was conducted on protein extracts from PEO4, PEO1, OVCAR3, 
2008 and SKOV3 cells, estrogen starved and transfected with either a control mimic, a 
control inhibitor, a tRF5-Glu mimic or a tRF5-Glu inhibitor. Protein lysates were 
collected at 48 hours post transfection. Densitometry of each band was measured and the 
relative ratio of BCAR3/-Actin is shown. (B) A schematic of the 50 base pair region of 
the BCAR3 3’UTR and predicted binding site for tRF5-Glu is shown with the wild type 
and mutant seed sequences listed below. Luciferase reporter plasmids were constructed 
containing the predicted binding site intact or mutated at two base pairs within the 
predicted seed region (designated by underlined letters). (C) Luciferase constructs with 
the wild type or mutant 50bp region of BCAR3 3’UTR were transfected into HEK293T, 
PEO4 and 2008 cells with a control mimic or a mimic of tRF5-Glu.  Transfections were 
performed in triplicate. The result was compared to a control mimic and error bars refer 
to +/- standard error (**** p-value <.001). 
 
Usage of an alternative poly-A site may modulate tRF5-Glu regulation of BCAR3 
expression in 2008 ovarian cancer cells  
The lack of response of BCAR3 expression to mimics or inhibitors of tRF5-Glu in 
SKOV3 and 2008 was reminiscent of miRNA studies where the 3’UTR in rapidly 
growing cells may be shortened thereby deleting a binding site for a miRNA repressor 
[222-224].  The 3’UTR of mRNAs contain many regulatory sites including, but not 
limited to, ncRNA binding, RNA binding protein binding sites and alternative poly A 
sites (APA) [225].  It has been shown that APA sites may be used in some rapidly 
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proliferating cells, thereby eliminating a regulatory region and shortening a normally 
longer 3’UTR [226]. Regulation of mRNA expression through RNA binding sites in the 
3’UTR are often affected by the use of tandem APA sites [227].  
The discrepancy between the regulation of BCAR3 by mimics of tRF5-Glu in 
some ovarian cancer cell lines in contrast to that of SKOV3 and 2008 cells raised the 
possibility that the 3’UTR of BCAR3 might have been truncated due to the use of an 
alternative tandem APA in the UTR and 5’ to the tRF5-Glu binding site. A poly-A site 
prediction search was conducted to determine if a tandem poly-A site is present in the 
BCAR3 3’UTR (Figure 12A) [225]. A qRT-PCR assay relating the total BCAR3 mRNA 
expression to the longer 3’UTR was developed and substantiated the hypothesis that a 
shorter UTR was used in SKOV3 and 2008 cells, while the more distal poly-A site was 
frequently utilized in PEO1, PEO4 and OVCAR3 cells (Figure 12B). Further 
confirmation was achieved by amplifying and cloning the BCAR3 3’UTR from the poly-
A containing fraction of total RNA from PEO4 and 2008 cell lines (Table 13).   
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Figure 12. APA sites in the 3’UTR of BCAR3 are utilized and may prevent 
regulation by tRF5-Glu. (A) Schematic diagram of the 3’UTR of BCAR3 designating 
the APA site (black box) and the predicted site for tRF5-Glu binding (grey box).  The 
length of the cloned 3’UTRs for BCAR3 are depicted starting from the stop codon of 
BCAR3. The primers used for qRT-PCR are designated by solid arrows for the amplicon 
in the coding region and hatched arrows are used to designate the 3’UTR specific 
primers.  (B) Relative expression of the longest BCAR3 3’UTR to total BCAR3 mRNA 
assayed by qRT-PCR for PEO4, PEO1, OVCAR3, 2008 and SKOV3 cells.   qRT-PCR 
experiments are replicates of three independent experiments and error bars refer to +/- 
standard error. 
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Table 13. Representative sequences of the 3’UTR of BCAR3 in ovarian cancer cells 
 
 
The qRT-PCR analysis and cloning of the 3’UTR sequences in PEO4 cells 
confirmed that in this cell line the distal poly-A is more frequently used, while in 2008 
proximal sites may be used for poly-A addition.  The use of the proximal poly-A site 
Representative sequences of the 3' UTR of BCAR3
Cell line Sequence
PEO4 full length
CCTGTAAAGCAGGCAGAGCTTTGATAACTCTCCAGAGAAC
CTTTAGAATATCTTTTCAAGTTTCCCCAGCTTCATCTTTGGG
AAAGCTTACTGTTTTTGATAAAGTAATAATGTGCAAATCTG
ACAATATACAAGCTTTTAGTATCCACAGGATATTAAACGTG
TAAATTGCACAGAGCACACTTATTTATGAATTGTCTAAAGT
TACTACTGATTTTAAAATGAATAATTTATTATTAAGGTAAC
TACTGCTAATGTTGATCAGCAAATTTAAGAGAAGACCTAG
CTATGTTGGCTGGTTGCTTTCTATTATCATGGTATTTGACCA
TTTTAGTTTTAATTCCATGTCAGATAAGTGTAAATAGAAGA
2008 full length
CCTGTAAAGCAGGCAGAGCTTTGATAACTCTCCAGAGAAC
CTTTAGAATATCTTTCCAAGTTTCCCCAGCTTCATCTTTGGG
AAAGCTTACTGTTTTTGATAAAGTAATAATGTGCAAATCTG
ACAATATACAAGCTTTTAGTATCCACAGGATATTAAACGTG
TAAATTGCACAGAGCACACTTATTTATGAATTGTCTAAAGT
TACTACTGATTTTAAAATGAATAATTTATTATTAAGGTAAC
TACTGCTAATGTTGATCAGCAAATTTAAGAGAAGACCTAG
CTATGTTGGCTGGTTGCTTTCTATTATCATGGTATTTGACCA
TTTTAGTTTTAATTCCATGTCAGATAAGTGTAAATAGAAGA
GTTTAAAAGCATGAAACATTTCAGAAGGTATCAGTTATAT
GATATTCTTTAAACAAATATGAAAAATGTAAATACTCATG
AATGAAAATACATCTTTTTGTG
2008 224 bp
CCTGTAAAGCAGGCAGAGCTTTGATAACTCTCCAGAGAAC
CTTTAGAATATCTTTTCAAGTTTCCCCAGCTTCATCTTTGGG
AAAGCTTACTGTTTTTGATAAAGTAATAATGTGCAAATCTG
ACAATATACAAGCTTTTAGTATCCACAGGATATTAAACGTG
TAAATTGCACAGAGCACACTTATTTATGAATTGTCTAAAGT
TACTACTGATTTTAAAATG
2008 125 bp
CCTGTAAAGCAGGCAGAGCTTTGATAACTCTCCAGAGAAC
CTTTAGAATATCTTTTCAAGTTTCCCCAGCTTCATCTTTGGG
AAAGCTTACTGTTTTTGATAAAGTAATAATGTGCAAATCTG
AC
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closest to the stop codon in BCAR3 prevents regulation of BCAR3 by tRF5-Glu because 
the binding site is not present in the shortened BCAR3 mRNA. This finding implies that 
the regulation of BCAR3 is more complicated than previously known and may vary 
between cell lines.   
 
Over expression of tRF5-Glu reduces ovarian cancer cell proliferation 
It had previously been shown that BCAR3 expression increased proliferation of 
breast cancer cells [205]. We hypothesized that knocking down BCAR3 expression in 
ovarian cancer cells would similarly inhibit the proliferation (that is, overall cell number 
resulting from the balance of cell death and cell division) of ovarian cancer cells.   
BCAR3 expression was down regulated with siRNAs targeting BCAR3. In both PEO4 
and 2008 cells siRNAs targeting the coding region of BCAR3 were able to block BCAR3 
expression (Figure 13).  The loss of BCAR3 and subsequent reduction of proliferation 
had not previously been shown in ovarian cancer cells. In Figure 14 we show that siRNA 
inhibition of BCAR3 results in a significant decrease of proliferation when compared to 
control.  
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Figure 13. Western analysis of BCAR3 protein expression following 48 hours 
treatment with control siRNA (con si) and BCAR3 siRNAs (ANG si1, 2) in PEO4 
and 2008 ovarian cancer cell lines. Densitometry of each band was measured and the 
relative ratio of BCAR3/-Actin is shown. 
 
 
Figure 14. Proliferation of ovarian cancer cells is inhibited by either siRNA to 
BCAR3 or mimics of tRF5-Glu.  (A) PEO4 cells transfected with either a control 
siRNA, siRNAs targeting BCAR3 or mimics of tRF5-Glu were grown in culture for up to 
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six days and then fixed and assessed by Sulforhodamine B (SRB) assay. Proliferation 
measures the overall cell number resulting from the balance of cell division and cell death 
over time.  Values are shown as percent of control (control siRNA transfected cells; set to 
100%) at day one, day three and day six.   (B) 2008 cells were transfected and grown as 
described above for PEO4 cells. Cell proliferation experiments are replicates of three 
independent experiments and error bars refer to +/- standard error.  p-value was less than 
0.05 for PEO4 and 2008 cells treated with siRNAs to BCAR3 and tRF5-Glu mimic on 
day six. 
 
Additionally, studies of tRFs in cancer cells have previously shown that 
increasing tRF concentration may decrease cancer cell proliferation. For example the 
over expression of tRF-1001 (tRF3-Ser) has been shown to decrease proliferation of 
prostate cancer cells [85]. Thus, it was logical to assess the ability of tRF5-Glu to alter 
the proliferation rate of ovarian cancer cells in culture. We found that mimics of tRF5-
Glu significantly reduced the proliferation of both PEO4 and 2008 cells (Figure 14). 
These results indicate that BCAR3 is not the only target of tRF5-Glu because mimics of 
tRF5-Glu do not alter BCAR3 expression in 2008 cells (Figure 11A). Therefore, tRF5-
Glu would be expected to bind to additional mRNA target sites in additional genes, 
similar to the mechanism of canonical miRNAs where multiple targets are common. 
Future studies will be needed to identify additional targets of tRF5-Glu.   
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Discussion 
Ovarian cancer is known to have the highest mortality rate of the gynecologic 
malignancies [228].  The high mortality rate is often attributed to the late stage of 
diagnosis, lack of treatment options and the molecular heterogeneity of the disease [228, 
229]. Next-generation sequencing is becoming routine in the clinical setting and adds to 
our understanding of tumor heterogeneity, however, much work is needed to define 
useful information from the massive amounts of data now clinically available [230].  The 
ncRNAs, including the miRNAs are frequently found highly expressed in next-generation 
sequencing studies and are adding to our understanding of tumor heterogeneity [197]. 
Even more recently many rRNA and tRNA fragments have been described and the tRFs 
are now being implicated in cancer biology [74].  
Studies of a variety of tRFs have shown that they are actively generated from mature 
tRNAs and the 5’tRFs are frequently generated by cleavage from tRNAs by ANG. ANG 
is a well characterized RNase previously associated with the process of angiogenesis, one 
of the hallmarks of cancer [231]. The biogenesis of tRF5-Glu has previously been shown 
to involve cleavage by ANG in response to respiratory syncytial virus [114]. We applied 
similar methods to confirm that ANG is responsible for the biogenesis of tRF5-Glu in 
ovarian cancer cell lines. siRNA inhibition of ANG followed by northern analysis and 
ligation PCR confirmed that with reduced expression of ANG, there is reduced 
expression of tRF5-Glu.  
tRFs have been confirmed to function in the stress response to regulate stress 
granule formation as well as to directly target the RNA binding protein, YBX1, and 
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prevent binding to its mRNA targets [94, 232].  Two other tRFs are known to directly 
bind mRNA targets in a manner similar to canonical miRNAs [129, 203]. Further 
indication that tRFs may function to regulate RNA targets has come from their inclusion 
in AGO HITS-CLIP data sets [201, 202, 233].   The CLASH data set is particularly 
informative because of its ability to link RNA-RNA hybrids, and indicates that both 
tRF5-Glu and a variant of tRF5-Glu, homologous to the former miR-2476, are able to 
target mRNAs in an AGO1 dependent manner [202]. As tRFs are further characterized it 
is expected that they will contribute to the complexity of tumor heterogeneity.  
BCAR3 was especially interesting as a potential target of tRF5-Glu because it has 
been extensively studied in breast cancer as a protein associated with anti-estrogen 
resistance [234].  BCAR3 has not been studied in ovarian cancer and little is known 
regarding its regulation at the mRNA level. Thus, we chose to examine this protein for its 
potential as a target of tRF5-Glu with the expectation that it would lead to new 
understanding of a regulatory mechanism previously undefined in this disease.        
Modifying the method of miR-Catch and using two luciferase reporter assays we 
were able to confirm that tRF5-Glu binds directly to the BCAR3 mRNA. The BCAR3 
specific probe allowed the pulldown of the BCAR3 mRNA and the associated tRF5-Glu 
and was not pulled down with a random probe. Luciferase assays confirmed the predicted 
site in the 3’ region of BCAR3 was capable of binding mimics of tRF5-Glu and allowing 
down regulation of the target.  We were also able to confirm that tRF5-Glu is capable of 
targeting BCAR3 mRNA expression in multiple cell lines, while in still others it appeared 
incapable of regulating BCAR3 protein expression.  APA sites have been shown to alter 
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miRNA regulation in rapidly growing cells and provide another layer of regulation 
through the 3’UTR of mRNA [226]. Our finding that BCAR3 has an APA site upstream 
from the tRF5-Glu binding site suggests that this may provide an alternative mechanism 
for the regulation of BCAR3.  
The expression of BCAR3 in breast cancer cells has been previously associated 
with increased proliferation [205]. In contrast, tRF-1001 has been reported to inhibit 
prostate cancer cell proliferation [85]. Taken together these two findings led to our 
hypothesis that increased expression of tRF5-Glu would reduce the proliferation of PEO4 
cells, due to direct binding of tRF5-Glu in the 3’ UTR of BCAR3. However, our studies 
also indicate that mimics of tRF5-Glu reduced the proliferation of 2008 cells, suggesting 
that other targets of tRF5-Glu are regulated in the 2008 cell line. These results and the 
regulation of apolipoprotein E receptor 2 (APOER2) by tRF5-Glu demonstrate that, much 
like miRNA regulators, tRF5-Glu has multiple targets [203].   
Future studies will be required to identify the impact of tRF5-Glu expression and 
regulation of its targets in ovarian cancer and its impact for patient outcome. The study of 
tRFs is just beginning and this group of ncRNAs may open the way for the development 
of new therapeutic targets as more information is gathered. tRFs add another layer of 
complexity to discerning the heterogeneity of gene expression and regulatory 
mechanisms of ncRNA.    
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Experimental Materials and Methods 
 
Cell culture and reagents 
Ovarian cancer cell lines PEO1, PEO4, SKOV3, 2008, OVCAR3 were provided 
by Dr. Monique Spillman [210-212] and HEK293T cells were obtained from ATCC 
(American Type Culture Collection, Manassas, VA). All the cell lines were grown in 
RPMI 1640 with 10% fetal bovine serum and Plasmocin (Invivogen, San Diego, CA). 
Estrogen depletion and addition studies were conducted using cells cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% charcoal stripped 
fetal bovine serum [235]. Cells were incubated at 37°C with 5% CO2 and have been 
tested to be mycoplasma free. 
 
RNA extraction, qRT-PCR and cloning of PCR products 
Total RNA was extracted from cells using miRNeasy (Qiagen, Valencia, CA) as 
previously described [236]. Equal amounts of RNA were reverse transcribed into cDNA 
using the miScript II RT Kit and qRT-PCR was conducted with miScript SYBR Green 
(Qiagen). mRNA expression was normalized to beta actin, while small RNA expression 
was normalized to RNU6B (RNU6B_13, Qiagen).   The polyA site was identified in 
BCAR3 from PEO4 and 2008 cells using Thermoscript RT (Invitrogen) and oligo dT as 
previously described [237].  PCR products were amplified using the 5’ forward BCAR3 
primer with the Universal reverse primer from Qiagen and amplified using GoTaq Green 
(Promega, Madison, WI).   Primers are listed in Table 14.  PCR products were cloned 
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into T-vector (Life Technologies, Carlsbad, CA) and sent for direct sequencing 
(University of Minnesota Genomic Center, Minneapolis, MN). 
 
Table 14. Sequences of primers and probes. 
Primer Type Sequence and information about the primer design 
adj-tRF5-Glu 
 
ggCCCTGTGGTCTAGTGGTTAGGATTC 
adjusted to achieve improved melting temperature 
RNU6B forward 
primer  
Commercially available RNU6B_13. It is critical that 
RNU6B_13 be used because RNU6B-11 does not work for these 
assays (Qiagen). 
BCAR3 forward  
TTGAAAGACACAACACAATGGCCATCGG 
BCAR3 reverse  
GGAACACATGTGGACTCTCTGCCTTC (cross exon) 
Beta actin forward  
ATCCACGAAACTACCTTCAACTC  
Beta actin  
reverse 
 
GAGGAGCAATGATCTTGATCTTC  (cross exon) 
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3’RNA adaptor 
[89] 
5’/5Phos/GAACACUGCGUUUGCUGGCUUUGAGAGUUCU
ACAGUCCGACGAUC/3ddC/-3’ 
tRF5-Glu probe 5’-
/56FAM/CGCTCTCGA/ZEN/ACACTGCGTTTGC/3IABkFQ/-
3’ 
RNU6B probe 5’-
/56FAM/TTTGAACAC/ZEN/TGCGTTTGCTGGC/3IABkFQ/-
3’ 
tRF5-Glu forward  
CCCTGTGGTCTAGTGGTTAGGATTC 
3’ adaptor reverse 
primer [89] 
 
CGTCGGACTGTAGAACTCTCAAAGC 
Luciferase 
construct BCAR3 
The amplified region included 415 of the 458 base pairs reported 
in GenBank as the 3’UTR of the human BCAR3 
(NM_001261408.1).   
Xho1 BCAR3 aacctcgagCCTGTAAAGCAGGCAGAGCTTTGA   
Not1 BCAR3 aaggatataagcggccgcgAATATCATATAACTGATACCTTCTGA
AATGTTTC 
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BCAR3 mut 
forward 
CAAGCTTTTAGTATCCAGACGATATTAAACGTG 
BCAR3 mut 
reverse 
CACGTTTAATATCGTCTGGATACTAAAAGCTTG 
BCAR3 3’end 
forward 
AGAGAAGACCTAGCTATGTTGGCTGGTTG 
 
Qiagen Universal 
reverse 
Use Qiagen universal reverse with BCAR3’ end forward and 
with tRF5-Glu adjusted primers. 
Biotin BCAR3 
capture probe 
5’-
/5BiotinTEG/ATGGCCATTGTGTTGTGTCTTTCAATTATG-
3’ 
Biotin random 
capture probe 
5’-
/5BiotinTEG/GATTAGTGTCACAACTTTTGTTCGTTGTTG-
3’ 
Xho1 50bp 
BCAR3 
TCGAAGTAATAATGTGCAAATCTGACAATATACAAGCT
TTTAGTATCCACAGGATAT 
Not1 50bp 
BCAR3 
GGCCATATCCTGTGGATACTAAAAGCTTGTATATTGTC
AGATTTGCACATTATTACT 
50bp BCAR3 mut 
forward 
TCGAAGTAATAATGTGCAAATCTGACAATATACAAGCT
TTTAGTATCCAGACGATAT 
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50bp BCAR3 mut 
reverse 
GGCCATATCGTCTGGATACTAAAAGCTTGTATATTGTC
AGATTTGCACATTATTACT 
 
 
Quantification of tRFs by Ligation qRT-PCR 
The sequence of the adapters, probes and primers for tRF quantification by 
Taqman qRT-PCR are included in Table 14. The ligated tRFs were prepared with 
methods described by Honda et al., [89].   RNA extracted from siRNA treated cells was 
treated with T4 polynucleotide kinase (T4PNK) to convert the 3’ cyclic phosphate group 
into a hydroxyl group prior to ligation of a 3’ linker and then copied into cDNA. A 
forward primer specific to either tRF5-Glu or U6 and a reverse primer specific to the 
linker were used to amplify targets from the total cDNA pool.  Ligated RNA were 
subjected to qRT-PCR using the QuantiTect Probe RT-PCR Kit (Qiagen). The quantified 
tRF5-Glu levels were normalized to RNU6B. 
The probe placement was determined by Sanger sequencing of the PCR product 
which identifies the base pairs at the junction of the tRF5-Glu and the linker. The 
sequence identified the specific variant of tRF5-Glu to be one base longer than that 
previously predicted to be cleaved by ANG [87].  Once the junction between the linker 
and the most 3’ base of tRF5-Glu and of U6 were determined we were able to design 
probes for ligation PCR (Table 14).  
 
Northern Blot 
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Northern blot analysis was modified from methods previously described [238]. 
Denaturing polyacrylamide gels (15%) containing 7M urea was used to separate small 
RNA.  Equivalent loading and RNA integrity were confirmed by gel imaging of the 
rRNA using a Licor FC imager. Blots were probed with the 5’-biotinylated RNA probes: 
tRF5-Glu probe (Table 14), and the miRNA marker miR-21 probe was used for size 
analysis (New England Biolabs, Ipswich, MA).  
 
Western Blot 
Protein was extracted from cells using Passive Lysis Buffer (Promega) and 
samples were loaded onto 4%-20% Mini-PROTEAN TGX gel (Bio-Rad Laboratories, 
Hercules, CA). The primary antibodies include rabbit anti-BCAR3 #A301-671A (Bethyl 
Laboratories, Montgomery, TX), ANG 1 (C-20): sc-1408 (Santa Cruz Biotechnology, 
Dallas, TX), rabbit anti-β-actin #4970 (Cell Signaling Technologies, Danvers, MA). All 
antibodies has been tested for specificity. 
 
Transfection with siRNA, mimics and inhibitors 
Cells were seeded 24h prior to transfection in 35mm petri dishes or 24-well plates 
and transfected with Lipofectamine 2000 (Invitrogen) according to manufacturer’s 
instructions. The Allstars negative control and the miScript inhibitor negative control 
were used in the transfection at a concentration of 1nM (Qiagen).  Mimics and inhibitors 
for tRF5-Glu (MSY0012067 and MIN0012067, Qiagen) were also used in the 
transfection at a concentration of 1nM. The siRNAs were obtained from Qiagen and 
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consisted of Gene Solution siRNA product number 1027416 as a control.  Two siRNAs 
were selected from each set of four for further use including Hs_BCAR3_3 SI00053102 
(BCAR3 siRNA 1), Hs_BCAR3_6 SI0381603 (BCAR3 siRNA 2), Hs_ANG_6 
SI02780197 (ANG siRNA 1) and Hs_ANG_7 SI03071866 (ANG siRNA 7). 
 
Luciferase Assay and constructs 
Luciferase constructs containing either 471 base pairs of the BCAR3 3’UTR or a 
50 base pair region containing the predicted binding site and a second construct, 
containing site directed mutations in the predicted binding site were prepared using 
methods as previously described [239].  The BCAR3 3’-UTR including the predicted 
binding site for tRF5-Glu was cloned into psiCheck-2 dual luciferase vector.  Mutant 
BCAR3 3’UTR luciferase vectors were generated using primers designed to exchange a 
C for a G and a G for a C in the tRF5-Glu predicted binding region.  These plasmids and 
a tRF5-Glu mimic were co-transfected into HEK293T cells. Finally, luciferase assays 
were conducted using the dual luciferase reporter kit (Promega).  All primer sequences 
for vector construction are included in Table 14.   
 
miR-Catch and BCAR3 mRNA pulldown 
Five variants of BCAR3 are listed in GenBank and each variant was subjected to 
unifold (IDTDNA.com) to identify regions that would remain single stranded and 
available for probe binding. A biotinylated probe targeting the BCAR3 mRNA was 
designed such that it would bind to a predicted single stranded region of the BCAR3 
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coding sequence and conjugated to a streptavidin labeled magnetic bead. A similar 
biotinylated probe was generated from a randomized sequence and used as a negative 
control.  Cell lysates from PEO4 cells following 48 hours of Estrogen stimulation were 
collected by resuspending and lysing cells in passive lysis buffer (Promega) and 
hybridizing for 90 minutes at 37 oC with either the BCAR3 specific probe or the 
randomized probe.  Magnetic beads were then captured on a Mylteni separator and 
washed with 1X PBS 3 times.  The flow through and magnetic particles were collected 
for RNA extraction.  RNA was converted to cDNA for qRT-PCR amplification and 
analysis for BCAR3 mRNA and tRF5-Glu were conducted.  All primer sequences for 
miR-Catch probes are included in Table 14.   
 
SRB proliferation assay 
SRB assays were used to measure cell proliferation, essentially as described by 
Skehan et al., [240], with a few modifications [241, 242].  The SRB assay measures total 
cellular protein, which has been shown to be linear with cell number [240]. PEO4 and 
2008 cells were seeded in 48 well-plates at a concentration of 1×104 cells/ml and grown 
under the described experimental conditions for up to 6 days. The cells were then fixed 
with ice-cold methanol containing 1% acetic acid. Subsequently, cells were incubated 
with 0.5% SRB solution for 1h at 37 °C, then rinsed 3-5 times with 1% acetic acid 
washed to remove unbound dye, and then air-dried.  Bound SRB was eluted with 10mM 
Tris, pH10, and the absorbance at 540 nm measured in a multi-well plate reader. Results 
were expressed as a percentage of signal of the controls.   
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Statistical analysis 
All the data were expressed as means with standard error and represent at least 
three independent experiments. Comparison of gene expression was made by using the 
Student’s t-test. A p-value less than 0.05 was considered to be significant. 
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Chapter 4: Conclusions and Future Directions 
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Summary and significance of results 
Given the low five-year survival rate of ovarian cancer patients, which is largely 
driven by non-specific symptoms and a lack of early diagnosis, a simple and effective 
method of early detection is urgently needed. Previously, I have discussed several widely 
used detection methods for ovarian cancer in Chapter 1, however, none of them are 
sufficient and specific enough to be applied in the early diagnosis of ovarian cancer. 
With the advance of deep sequencing techniques for nucleic acids, ncRNAs have 
recently been identified in cancer patients’ tissue samples as well as in liquid biopsies. 
Several ncRNAs have been identified to be associated with the diagnosis and prognosis 
of multiple cancers [73]. Liquid biopsy samples, such as urine, act as a good source for 
biomarker discovery due to the easy accessibility and the ready collection from patients. 
In my project the use of urine was especially helpful due to the inaccessible nature of the 
ovaries.  In reports from our physician collaborators (MA Spillman and K Behbakht), the 
use of urine was preferable in this disease.   
My first hypothesis was that exRNAs are present and detectable in the urine 
obtained from ovarian cancer patients. To test this hypothesis, we have performed small 
RNA deep sequencing on urine samples of ovarian cancer patients with late stage disease. 
Our goal was to identify potential ncRNA biomarkers of ovarian cancer. In this study, we 
have developed a novel method to isolate exRNAs from a small volume of urine instead 
of urinary exosomes which requires a large volume of urine. The use of small volumes of 
urine rather than large amount of urine is advantageous for several reasons.  Although 
exosomes from urine are more often used in other published studies, limited analysis of 
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exosomes misses the totality of the RNA in urine. While it is possible to collect large 
volumes of urine, it is harder to handle large volumes in the clinic. When the ultimate 
goal is a clinically applicable method, it is better to start with a stream lined approach to 
begin with.  The first hypothesis that there are detectable ncRNAs in urine proved to be 
correct and a larger number of potential biomarkers were identified than initially 
expected. 
In the follow-up analysis, we have compared the classes of exRNAs among all 
eight urine samples. Notably, functional ncRNA were present at significant levels and 
included certain miRNAs and a novel class of small ncRNAs named tRFs. Analysis of 
the deep sequencing data was performed to obtain the top 5 miRNAs and tRNA 
fragments, which helps narrow down potential biomarker candidates or functional 
molecular candidates for potential biomarkers of ovarian cancer (Table 7 and Table 8).   
  The discovery of several tRFs in the urine of ovarian cancer patients led to my 
project described in Chapter 3, where I worked to discover the function of a specific 
tRF, tRF5-Glu. Following extensive bioinformatics analysis of tRF5-Glu expression, 
tRF5-Glu was the most highly expressed in all eight urine samples. In addition, tRF5-Glu 
had been misclassified as miR-2476 and thought to be specific to the cow and pig and not 
found in humans (http://www.targetscan.org/vert_61/).  Our first goal was to determine if 
this ncRNA could originate from the ovarian tumor.  The reasoning was that, even though 
tRF5-Glu was identified in the urine of patients with ovarian cancer, it could be either 
secreted from the ovarian cancer cells themselves into circulation or from some other 
sources, such as bladder cells and urinary tract cells into urine directly which have direct 
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access to urine. Several studies have indicated that miRNAs can be released from cells 
into circulation through cellular mechanisms including as cargo in exosomes, 
microvesicles, proteins and lipid complexes [158, 243-245]. Reports of miRNAs from 
other tissue sites, such as the breast, helped to convince us the possible origin of tRF5-
Glu from ovarian cancer cells [73]. We went on to show that tRF5-Glu is expressed in 
five different ovarian cancer cell lines (Figure 6).  
To our knowledge, only a few tRFs has been studied in cancer cells and a tRF, 
tRF-Lys, is identified as a possible prognostic biomarker of high-grade serous ovarian 
cancer [75]. Thus, the tRFs identified in our study could be functional molecules in 
ovarian cancer cells and may be associated with tumor growth and progression. At the 
time of these studies, the function of tRFs had not been studied in ovarian cancer cells. In 
Chapter 3, we further studied the function of tRF5-Glu. We were able to confirm that 
ANG is involved in the biogenesis of tRF5-Glu from the mature tRNA-Glu and the 
production of tRF5-Glu was in response to the estrogen treatment in ovarian cancer cell 
line, PEO4. We also evaluated that tRF5-Glu binds to the 3’UTR of BCAR3 gene and 
regulates its expression in a manner similar to a miRNA. In addition, the overexpression 
of tRF5-Glu also inhibits the proliferation of ovarian cancer cells not only through 
downregulating BCAR3, but may also regulate through targeting other pathways. Unlike 
previous work showing certain tRFs regulate the translation process in cooperation with 
particular RNA binding proteins, my work exhibits another pattern of how a tRF is 
involved in the regulation of tumor growth. This work also provides a model for studying 
the functions of other tRFs as miRNA-like regulators in cancer cells. The results and 
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methods used in this study were published recently in two manuscripts (Chapter 2 and 
Chapter 3). 
 
Reflections and future directions 
A novel method to identify potential exRNA biomarkers for ovarian cancer was 
proposed in Chapter 2 and a novel tRF, tRF5-Glu, was identified from those studies. 
Evaluation of tRF5-Glu expression and its function were then conducted in Chapter 3 to 
confirm the role of tRF5-Glu in ovarian cancer cells. In this section, possible challenges 
and future directions will be addressed to better clarify the potential impact of my studies. 
In Chapter 2, we have performed a pilot small RNA deep sequencing study in the 
urine samples collected from 8 patients to seek potential RNA biomarkers. While several 
miRNAs and tRFs were found to be highly enriched in urine, a future study containing a 
larger number of urine samples needs to be conducted to further test the possibility that 
certain tRFs or miRNAs are potential biomarkers of ovarian cancer. While we were 
looking at the pilot small RNA deep sequencing database, rRNA fragments are actually 
much more prevalent than miRNAs and tRFs discussed in my study. However, there is 
still less known about the function of rRNA fragments at this time and it is unknown if 
they are associated with cancer diagnosis or tumor biology.    
Among the top 5 miRNAs summarized in Table 7, miR-10b was identified as the 
top one in all samples, which led to a future question whether miR-10b could be a 
potential biomarker of ovarian cancer or if it plays a role during ovarian cancer growth 
and progression. Previous studies have already evaluated the oncogenic role of miRNA-
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10b in many cancer sites including non-small cell lung cancer and glioblastoma [246, 
247]. And we have found it regulates the NCOR2 mRNA and protein expression in 
ovarian cancer cells, which in turn affects the expression of androgen receptor (AR). Our 
laboratory previously showed that the downregulation of NCOR2 by miR-125b allows 
increased expression of the AR [236]. One future goal in the Bemis laboratory will be to 
further explore the functional mechanisms of miRNA-10b in ovarian cancer cells.  
Finally, we analyzed the tRFs identified in patients urine and summarized the 
top5 tRFs in Table 8. Although we only studied the two most abundant variants of tRF5-
Glu-CTC in urine samples and in an available database of human samples, the same 
analysis could be applied to the study of other tRFs, such as tRF-Gly, tRF-Lys, tRF-Val 
and tRF-His (Table 10). Previous studies have shown that the fragment from tRNA-Lys 
enhances the proliferation of prostate cancer cells, while another study showed that a 
fragment from tRNA-His could inhibit the translation initiation process in human 
osteosarcoma epithelial cells [89, 131]. These studies illustrate that the implications of 
tRF expression may be broader than firstly thought and more extensive than standard 
miRNAs. There remain many unanswered questions in the study of tRFs including the 
functional study of less known tRFs as well as the different tRF variants from the same 
mature tRNA. 
The studies in Chapter 3 use tRF5-Glu as a model to study the function of the 
tRF in ovarian cancer. We characterized the functions and detailed the expression of this 
specific tRF in ovarian cancer cells. However, several challenges were encountered in 
this work and we have developed possible solutions to conquer them. A clear limitation 
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to the tRF study is the lack of methods to quantify the exact amount of tRFs. Due to the 
short sequences and origins of tRFs, a regular qRT-PCR is not applicable to measure the 
exact copies of tRFs. Thus, in our study, we have adapted a method called ligation PCR 
from Honda et al. to the study of tRF5-Glu expression thereby allowing us to determine 
the precise levels of tRF5-Glu [89]. In this method, a specific TaqMan probe was 
designed to bind to the junction of the tRF and the 3’ linker. Furthermore, with the 
binding of two primers, one at the 5’ end of tRF5-Glu and the other at the 3’ linker 
correspondingly, only ligated tRF5-Glu will be amplified and the fluorescence can then 
be measured to tell the exact amount of tRF5-Glu. However, one TaqMan probe can only 
be matched with one ligated tRF5-Glu. Given the multiple variants of tRF5-Glu, we were 
able to pick up the most prevalent variant based on our sequencing and cloning results, 
while it does not represent the total levels of each type of variant of tRF5-Glu. If a more 
accurate measurement of tRF5-Glu levels in cells is required, it would be the combination 
of multiple TaqMan probes targeting all possible tRF5-Glu variants or small RNA deep 
sequencing to identify all the variants, which could be time-consuming and costly. Thus, 
although ligation PCR has been developed to quantify the levels of tRFs, it requires more 
improvement to measure the total amount of tRFs. 
Another challenge is the collection conditions for RNA extraction to study tRFs. 
In 2009, Fu et al. described that the cleavage of tRNA into tRFs is a stress-induced 
response [87]. tRFs may be generated in response to many stresses including starvation, 
such as PBS starvation as short as 30min, would induce the production of tRFs [87]. This 
raises a concern, if cells are not collected properly, whether tRFs measured by ligation 
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PCR and Northern blot represent the real-time amount in cells under different treatments. 
Unfortunately, there is a lack of details available about cell collection and RNA 
extraction in most studies of tRFs. In my study, we have used two different methods to 
collect cells for RNA extraction. One way is a 15min exposure to passive lysis buffer 
(Promega) incubation first, then add 700µl Qiazol (Qiagen) to save for RNA extraction; 
the other way is adding 700µl Qiazol to collect cells directly and then saving for RNA 
extraction. Two Northern blots of tRF5-Glu were shown in Chapter 3 to represent the 
first method (Figure 6B) and the second method (Figure 9D). Even though there is 
detectable tRF5-Glu bands in both Northern blots, it appears that there is a cleaner 
background and higher amount of tRF5-Glu in the first Northern Blot where cells 
undergo 15min of lysis buffer treatment. It is likely that the gentle lysis buffer treatment 
mimics the starvation process and it somehow increases the amount of tRFs and then 
improves the sensitivity of the Northern blot. Interestingly, I have obtained significant 
results from both collection methods but more studies need to be done to identify the 
optimal way to collect cells for RNA extraction and tRF study. 
In studies of the function of tRF5-Glu we used luciferase assay to study if there is 
direct regulation between tRF5-Glu and BCAR3 and we observed a 30-40% decrease for 
the relative luciferase activity (Figure 10D). Although significant, compared to the 
activity of miRNAs in luciferase assay where there is usually more than a 50% decrease, 
it indicates a potential difference in the RNA interference machinery between regulation 
by tRF and the mechanism of miRNA regulation. tRFs have been shown to be associated 
with different AGOs (Ago1-Ago4) [85], but it is possible that novel proteins may be 
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involved in this particular silencing complex, which needs to be further examined in 
future studies. Many questions remain about the regulatory mechanisms of tRFs and their 
role in the regulation of gene expression.  
In terms of the effects of tRF5-Glu on ovarian cancer cell proliferation, we have 
shown that overexpression of tRF5-Glu inhibits ovarian cancer cell growth in the PEO4 
and 2008 cell lines. However, the mechanism of regulation must be different because 
tRF5-Glu only regulates BCAR3 in PEO4 cells and BCAR3 is not regulated by tRF5-Glu 
in 2008 cells. We have confirmed that at least part of this difference is due to the 
reduction in the expression of the full length 3’ UTR of BCAR3 in 2008 cells (Figure 
12). The observance of reduced cell proliferation of 2008 cells treated by tRF5-Glu 
mimic indicates the possibility of multiple targets of tRF5-Glu in ovarian cancer cells. 
Multiple targets for tRFs is a reminiscent of the function of miRNAs and may be a 
similarity to other ncRNAs. Using the predicative software, TargetScan, and the methods 
describe in Chapter 3, further study of other potential targets regulated by tRF5-Glu is 
feasible. Future characterization of additional targets of tRF5-Glu will also provide new 
insight and advance the understanding of the novel functions of tRFs in cancer cells. 
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